1
|
Thompson DL, Welsh K, Alimchandani M. Adverse event reporting to US Food and Drug Administration and risk evaluation and mitigation strategies. Mol Ther 2023; 31:918. [PMID: 36931267 PMCID: PMC10124070 DOI: 10.1016/j.ymthe.2023.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 03/03/2023] [Accepted: 03/03/2023] [Indexed: 03/18/2023] Open
Affiliation(s)
- Deborah L Thompson
- US Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
| | - Kerry Welsh
- US Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
| | - Meghna Alimchandani
- US Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
| |
Collapse
|
2
|
Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM, Schlaudecker E, Lang SM, Barnett ED, Ruberg FL, Smith MJ, Campbell MJ, Lopes RD, Sperling LS, Baumblatt JA, Thompson DL, Marquez PL, Strid P, Woo J, Pugsley R, Reagan-Steiner S, DeStefano F, Shimabukuro TT. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA 2022; 327:331-340. [PMID: 35076665 PMCID: PMC8790664 DOI: 10.1001/jama.2021.24110] [Citation(s) in RCA: 363] [Impact Index Per Article: 181.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
IMPORTANCE Vaccination against COVID-19 provides clear public health benefits, but vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID-19 vaccination are unclear. OBJECTIVE To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US. DESIGN, SETTING, AND PARTICIPANTS Descriptive study of reports of myocarditis to the Vaccine Adverse Event Reporting System (VAERS) that occurred after mRNA-based COVID-19 vaccine administration between December 2020 and August 2021 in 192 405 448 individuals older than 12 years of age in the US; data were processed by VAERS as of September 30, 2021. EXPOSURES Vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna). MAIN OUTCOMES AND MEASURES Reports of myocarditis to VAERS were adjudicated and summarized for all age groups. Crude reporting rates were calculated across age and sex strata. Expected rates of myocarditis by age and sex were calculated using 2017-2019 claims data. For persons younger than 30 years of age, medical record reviews and clinician interviews were conducted to describe clinical presentation, diagnostic test results, treatment, and early outcomes. RESULTS Among 192 405 448 persons receiving a total of 354 100 845 mRNA-based COVID-19 vaccines during the study period, there were 1991 reports of myocarditis to VAERS and 1626 of these reports met the case definition of myocarditis. Of those with myocarditis, the median age was 21 years (IQR, 16-31 years) and the median time to symptom onset was 2 days (IQR, 1-3 days). Males comprised 82% of the myocarditis cases for whom sex was reported. The crude reporting rates for cases of myocarditis within 7 days after COVID-19 vaccination exceeded the expected rates of myocarditis across multiple age and sex strata. The rates of myocarditis were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively). There were 826 cases of myocarditis among those younger than 30 years of age who had detailed clinical information available; of these cases, 792 of 809 (98%) had elevated troponin levels, 569 of 794 (72%) had abnormal electrocardiogram results, and 223 of 312 (72%) had abnormal cardiac magnetic resonance imaging results. Approximately 96% of persons (784/813) were hospitalized and 87% (577/661) of these had resolution of presenting symptoms by hospital discharge. The most common treatment was nonsteroidal anti-inflammatory drugs (589/676; 87%). CONCLUSIONS AND RELEVANCE Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men. This risk should be considered in the context of the benefits of COVID-19 vaccination.
Collapse
Affiliation(s)
- Matthew E. Oster
- US Centers for Disease Control and Prevention, Atlanta, Georgia
- School of Medicine, Emory University, Atlanta, Georgia
- Children’s Healthcare of Atlanta, Atlanta, Georgia
| | - David K. Shay
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - John R. Su
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Julianne Gee
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Karen R. Broder
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | | | | | - Sean M. Lang
- Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
| | | | | | | | | | | | - Laurence S. Sperling
- US Centers for Disease Control and Prevention, Atlanta, Georgia
- School of Medicine, Emory University, Atlanta, Georgia
| | | | | | | | - Penelope Strid
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Jared Woo
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | - River Pugsley
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Frank DeStefano
- US Centers for Disease Control and Prevention, Atlanta, Georgia
| | | |
Collapse
|
3
|
Thompson DL. Comment on 'Position statement on the role of nurses in therapeutic patient education in atopic dermatitis'. J Eur Acad Dermatol Venereol 2021; 36:e341-e342. [PMID: 34753199 DOI: 10.1111/jdv.17799] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- D L Thompson
- School of Nursing and Midwifery, Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.,Women's and Children's Health Network, North Adelaide, SA, Australia
| |
Collapse
|
4
|
Magill SS, O'Leary E, Ray SM, Kainer MA, Evans C, Bamberg WM, Johnston H, Janelle SJ, Oyewumi T, Lynfield R, Rainbow J, Warnke L, Nadle J, Thompson DL, Sharmin S, Pierce R, Zhang AY, Ocampo V, Maloney M, Greissman S, Wilson LE, Dumyati G, Edwards JR. Antimicrobial Use in US Hospitals: Comparison of Results From Emerging Infections Program Prevalence Surveys, 2015 and 2011. Clin Infect Dis 2021; 72:1784-1792. [PMID: 32519751 PMCID: PMC7976440 DOI: 10.1093/cid/ciaa373] [Citation(s) in RCA: 45] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Accepted: 04/03/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND In the 2011 US hospital prevalence survey of healthcare-associated infections and antimicrobial use 50% of patients received antimicrobial medications on the survey date or day before. More hospitals have since established antimicrobial stewardship programs. We repeated the survey in 2015 to determine antimicrobial use prevalence and describe changes since 2011. METHODS The Centers for Disease Control and Prevention's Emerging Infections Program sites in 10 states each recruited ≤25 general and women's and children's hospitals. Hospitals selected a survey date from May-September 2015. Medical records for a random patient sample on the survey date were reviewed to collect data on antimicrobial medications administered on the survey date or day before. Percentages of patients on antimicrobial medications were compared; multivariable log-binomial regression modeling was used to evaluate factors associated with antimicrobial use. RESULTS Of 12 299 patients in 199 hospitals, 6084 (49.5%; 95% CI, 48.6-50.4%) received antimicrobials. Among 148 hospitals in both surveys, overall antimicrobial use prevalence was similar in 2011 and 2015, although the percentage of neonatal critical care patients on antimicrobials was lower in 2015 (22.8% vs 32.0% [2011]; P = .006). Fluoroquinolone use was lower in 2015 (10.1% of patients vs 11.9% [2011]; P < .001). Third- or fourth-generation cephalosporin use was higher (12.2% vs 10.7% [2011]; P = .002), as was carbapenem use (3.7% vs 2.7% [2011]; P < .001). CONCLUSIONS Overall hospital antimicrobial use prevalence was not different in 2011 and 2015; however, differences observed in selected patient or antimicrobial groups may provide evidence of stewardship impact.
Collapse
Affiliation(s)
- Shelley S Magill
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Erin O'Leary
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- Lantana Consulting Group, Thetford, Vermont, USA
| | - Susan M Ray
- Department of Medicine, Emory University, Atlanta, Georgia, USA
- Georgia Emerging Infections Program, Decatur, Georgia, USA
| | | | | | - Wendy M Bamberg
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Helen Johnston
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Sarah J Janelle
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Tolulope Oyewumi
- Colorado Department of Public Health and Environment, Denver, Colorado, USA
| | - Ruth Lynfield
- Minnesota Department of Health, St Paul, Minnesota, USA
| | - Jean Rainbow
- Minnesota Department of Health, St Paul, Minnesota, USA
| | - Linn Warnke
- Minnesota Department of Health, St Paul, Minnesota, USA
| | - Joelle Nadle
- California Emerging Infections Program, Oakland, California, USA
| | | | | | | | | | | | - Meghan Maloney
- Connecticut Emerging Infections Program, Hartford and New Haven, Connecticut, USA
| | - Samantha Greissman
- Connecticut Emerging Infections Program, Hartford and New Haven, Connecticut, USA
| | - Lucy E Wilson
- Maryland Department of Health and University of Maryland Baltimore County, Baltimore, Maryland, USA
| | - Ghinwa Dumyati
- New York Emerging Infections Program and University of Rochester Medical Center, Rochester, New York, USA
| | - Jonathan R Edwards
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
5
|
Magill SS, O’Leary E, Ray SM, Kainer MA, Evans C, Bamberg WM, Johnston H, Janelle SJ, Oyewumi T, Lynfield R, Rainbow J, Warnke L, Nadle J, Thompson DL, Sharmin S, Pierce R, Zhang AY, Ocampo V, Maloney M, Greissman S, Wilson LE, Dumyati G, Edwards JR, Chea N, Neuhauser MM. Assessment of the Appropriateness of Antimicrobial Use in US Hospitals. JAMA Netw Open 2021; 4:e212007. [PMID: 33734417 PMCID: PMC7974639 DOI: 10.1001/jamanetworkopen.2021.2007] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
IMPORTANCE Hospital antimicrobial consumption data are widely available; however, large-scale assessments of the quality of antimicrobial use in US hospitals are limited. OBJECTIVE To evaluate the appropriateness of antimicrobial use for hospitalized patients treated for community-acquired pneumonia (CAP) or urinary tract infection (UTI) present at admission or for patients who had received fluoroquinolone or intravenous vancomycin treatment. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study included data from a prevalence survey of hospitalized patients in 10 Emerging Infections Program sites. Random samples of inpatients on hospital survey dates from May 1 to September 30, 2015, were identified. Medical record data were collected for eligible patients with 1 or more of 4 treatment events (CAP, UTI, fluoroquinolone treatment, or vancomycin treatment), which were selected on the basis of common infection types reported and antimicrobials given to patients in the prevalence survey. Data were analyzed from August 1, 2017, to May 31, 2020. EXPOSURE Antimicrobial treatment for CAP or UTI or with fluoroquinolones or vancomycin. MAIN OUTCOMES AND MEASURES The percentage of antimicrobial use that was supported by medical record data (including infection signs and symptoms, microbiology test results, and antimicrobial treatment duration) or for which some aspect of use was unsupported. Unsupported antimicrobial use was defined as (1) use of antimicrobials to which the pathogen was not susceptible, use in the absence of documented infection signs or symptoms, or use without supporting microbiologic data; (2) use of antimicrobials that deviated from recommended guidelines; or (3) use that exceeded the recommended duration. RESULTS Of 12 299 patients, 1566 patients (12.7%) in 192 hospitals were included; the median age was 67 years (interquartile range, 53-79 years), and 864 (55.2%) were female. A total of 219 patients (14.0%) were included in the CAP analysis, 452 (28.9%) in the UTI analysis, 550 (35.1%) in the fluoroquinolone analysis, and 403 (25.7%) in the vancomycin analysis; 58 patients (3.7%) were included in both fluoroquinolone and vancomycin analyses. Overall, treatment was unsupported for 876 of 1566 patients (55.9%; 95% CI, 53.5%-58.4%): 110 of 403 (27.3%) who received vancomycin, 256 of 550 (46.6%) who received fluoroquinolones, 347 of 452 (76.8%) with a diagnosis of UTI, and 174 of 219 (79.5%) with a diagnosis of CAP. Among patients with unsupported treatment, common reasons included excessive duration (103 of 174 patients with CAP [59.2%]) and lack of documented infection signs or symptoms (174 of 347 patients with UTI [50.1%]). CONCLUSIONS AND RELEVANCE The findings suggest that standardized assessments of hospital antimicrobial prescribing quality can be used to estimate the appropriateness of antimicrobial use in large groups of hospitals. These assessments, performed over time, may inform evaluations of the effects of antimicrobial stewardship initiatives nationally.
Collapse
Affiliation(s)
- Shelley S. Magill
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Erin O’Leary
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
- Lantana Consulting Group, Thetford, Vermont
| | - Susan M. Ray
- Department of Medicine, Emory University, Atlanta, Georgia
- Georgia Emerging Infections Program, Decatur
| | - Marion A. Kainer
- Tennessee Department of Health, Nashville
- Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee
- Department of Infectious Diseases, Western Health, Melbourne, Victoria, Australia
| | | | - Wendy M. Bamberg
- Colorado Department of Public Health and Environment, Denver
- Medical Epidemiology Consulting, Denver, Colorado
| | - Helen Johnston
- Colorado Department of Public Health and Environment, Denver
| | | | - Tolulope Oyewumi
- Colorado Department of Public Health and Environment, Denver
- Department of Healthcare Management, University of Denver, Colorado
| | | | | | - Linn Warnke
- Minnesota Department of Health, St Paul
- Hennepin County Public Health, Minneapolis, Minnesota
| | | | - Deborah L. Thompson
- New Mexico Department of Health, Santa Fe
- Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
| | - Shamima Sharmin
- New Mexico Department of Health, Santa Fe
- Infection Prevention and Control Department, University of New Mexico Hospital, Albuquerque
| | | | | | | | - Meghan Maloney
- Connecticut Emerging Infections Program, Hartford and New Haven
| | - Samantha Greissman
- Connecticut Emerging Infections Program, Hartford and New Haven
- Department of Medicine, Columbia–New York Presbyterian Hospital
| | - Lucy E. Wilson
- Maryland Department of Health, Baltimore
- University of Maryland Baltimore County, Baltimore
| | - Ghinwa Dumyati
- New York Emerging Infections Program, Rochester
- University of Rochester Medical Center, Rochester, New York
| | - Jonathan R. Edwards
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Nora Chea
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Melinda M. Neuhauser
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| |
Collapse
|
6
|
Oberhaus EL, Thompson DL, Kerrigan LE, Chapman AM. Plasma prolactin, thyroid-stimulating hormone, melanocyte-stimulating hormone, and adrenocorticotropin responses to thyrotropin-releasing hormone in mares treated with detomidine and butorphanol. Domest Anim Endocrinol 2021; 74:106536. [PMID: 32871339 DOI: 10.1016/j.domaniend.2020.106536] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Revised: 06/25/2020] [Accepted: 08/04/2020] [Indexed: 10/23/2022]
Abstract
Stress or excitement is a concern when performing endocrine tests on fractious horses. Sedation may be a solution; however, perturbation of test results may preclude useful information. Thyrotropin-releasing hormone (TRH) is a known stimulator of prolactin, thyroid-stimulating hormone (TSH), melanocyte-stimulating hormone (MSH), and ACTH. Thyrotropin-releasing hormone-induced ACTH is a diagnostic tool for the assessment of endocrinopathies such as pituitary pars intermedia dysfunction. It is unknown if drugs commonly used for sedation alter endocrine responses. The objective of this study was to assess the effects of detomidine (DET) and butorphanol on endocrine responses to TRH. Nine light horse mares were used in a replicated 3 × 3 Latin square with the following treatments: saline, DET, and detomidine + butorphanol (DET/BUT), all administered intravenously at 0.01 mg/kg BW. A 1-wk washout period was allowed between phases, all of which were performed in December. Blood samples were collected at -10 and 0 min before treatment and 5 and 10 min post-treatment. Administration of 1 mg TRH occurred 10 min post-treatment, and blood sampling continued 5, 10, 20, and 30 min post-TRH. Data were analyzed by ANOVA as a replicated Latin square with repeated sampling. Plasma prolactin increased (P < 0.0001) after TRH in all groups, rapidly peaking at 5 min in drug-treated mares and 40 min in saline-treated mares. The peak prolactin response to TRH was 2-fold higher (P < 0.0001) in saline-treated mares compared with those drug-treated. A peak rise in plasma TSH was observed in DET/BUT-treated mares 10 min after TSH and was greater (P ≤ 0.007) compared with DET- and saline-treated mares. Plasma MSH was stimulated (P = 0.001) by DET and DET/BUT before TRH, and the peak MSH response to TRH was greater (P < 0.0001) in drug-treated mares, although not hastened as observed with prolactin and TSH. A peak rise in ACTH was observed in drug-treated mares 5 min after administration of TRH, whereas a peak rise was observed in control mares 10 min post-TRH and was almost 2-fold lower (P = 0.05) than the peak observed in DET and DET/BUT-treated mares. Basal ACTH concentrations were not affected by DET or DET/BUT, indicating that sedation with these compounds may be achieved when needing to measure basal plasma ACTH. Treatment with DET and DET/BUT did alter the prolactin, TSH, MSH, and ACTH responses to TRH; therefore, the use of these drugs may not be advisable when assessing endocrine responses to TRH stimulation.
Collapse
Affiliation(s)
- E L Oberhaus
- School of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge, LA, USA.
| | - D L Thompson
- School of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge, LA, USA
| | - L E Kerrigan
- School of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge, LA, USA
| | - A M Chapman
- Department of Veterinary Clinical Sciences, Louisiana State University School of Veterinary Medicine, Baton Rouge, LA, USA
| |
Collapse
|
7
|
Magill SS, O’Leary E, Ray SM, Morabit S, Perry L, Kainer MA, Beard RH, Bamberg W, Johnston HL, Lynfield R, Rainbow J, Warnke L, Nadle J, Thompson DL, Sievers MM, Sharmin S, Hancock EB, Pierce R, Zhang AY, Maloney M, Wilson LE, Buhr N, Richards K, Dumyati G, Edwards JR. 1859. Prevalence of Antimicrobial Use in US Hospital Patients, 2011 vs. 2015. Open Forum Infect Dis 2018. [PMCID: PMC6252926 DOI: 10.1093/ofid/ofy210.1515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background Antimicrobial stewardship (AS) is increasingly recognized as an essential component of patient safety programs. In a US hospital prevalence survey in 2011, 50% of patients received antimicrobial drugs (ADs). The survey was repeated in 2015 to describe changes in inpatient antimicrobial use, approximately one year after CDC published the “Core Elements of Hospital Antibiotic Stewardship Programs.” Methods Emerging Infections Program (EIP) sites in 10 states recruited up to 25 hospitals each, seeking to re-engage hospitals that participated in the 2011 survey. Hospitals selected survey dates from May to September 2015 and completed AS questionnaires. Patients were randomly sampled from the hospital census on the survey date. EIP staff retrospectively reviewed medical records to collect AD data. Percentages of patients on ADs on the survey date or the day before were compared using chi-square tests (SAS 9.4, OpenEpi 3.01). Results In 2015, among 148 hospitals participating in both surveys, 29 (19.6%) reported having no AS team (AST); 63 (42.6%) had ASTs for <4 years, and 56 (37.8%) had ASTs for ≥4 years. Antimicrobial use prevalence in 2015 was approximately 50% in hospitals with and without ASTs. Percentages of patients on ADs was not different in 2015 (4,590/9,169, 50.1%) compared with 2011 (4,606/9,283, 49.6%, P = 0.55). Antimicrobial use prevalence in most hospital locations did not change, although the percentage of neonatal intensive and special care unit patients on ADs was lower in 2015 compared with 2011 (22.1% vs. 30.7%, P = 0.005). The percentage of patients on fluoroquinolones was lower in 2015, while percentages of patients on carbapenems or cephalosporins were higher in 2015 than in 2011 (figure). ![]()
Conclusion Some observed differences between 2011 and 2015 provide evidence of stewardship impact. The decrease in antimicrobial use in selected neonatal locations may reflect implementation of tools to improve neonatal sepsis prescribing, while decreases in fluoroquinolone use may reflect efforts to prevent Clostridium difficile infections. However, our data also suggest that reductions in some ADs are offset by increases in others, supporting the need for ongoing work to identify the most effective AS strategies. Disclosures All authors: No reported disclosures.
Collapse
Affiliation(s)
| | - Erin O’Leary
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Susan M Ray
- Emory University School of Medicine, Atlanta, Georgia
- Georgia Emerging Infections Program, Decatur, Georgia
| | - Susan Morabit
- Georgia Emerging Infections Program, Decatur, Georgia
| | - Lewis Perry
- Georgia Emerging Infections Program, Decatur, Georgia
| | | | | | - Wendy Bamberg
- Colorado Department of Public Health and Environment, Denver, Colorado
| | - Helen L Johnston
- Colorado Department of Public Health and Environment, Denver, Colorado
| | | | - Jean Rainbow
- Minnesota Department of Health, St. Paul, Minnesota
| | - Linn Warnke
- Minnesota Department of Health, St. Paul, Minnesota
| | - Joelle Nadle
- California Emerging Infections Program, Oakland, California
| | - Deborah L Thompson
- Presbyterian Healthcare Services, Albuquerque, New Mexico
- New Mexico Department of Health, Santa Fe, New Mexico
| | | | | | | | | | | | | | | | - Nicolai Buhr
- Maryland Department of Health, Baltimore, Maryland
| | | | - Ghinwa Dumyati
- New York Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York
| | | | | |
Collapse
|
8
|
Abanyie-Bimbo F, O’Leary E, Nadle J, Thompson DL, Muleta D, Kainer MA, Epstein L, Magill SS. 275. Evaluation of Vancomycin Prescribing Quality in Hospitalized Pediatric Patients. Open Forum Infect Dis 2018. [PMCID: PMC6255663 DOI: 10.1093/ofid/ofy210.286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Background Vancomycin is the most common antimicrobial drug administered to hospitalized patients, including children >90 days old, although the prevalence of β-lactam antibiotic resistance among Gram-positive pathogens is relatively low in children. Reducing inappropriate vancomycin use in children can reduce harm from antibiotic-associated adverse events and antimicrobial resistance (AR). We developed an approach to evaluating pediatric intravenous (IV) vancomycin prescribing quality using medical record data. Methods Hospitals in three Emerging Infections Program (EIP) sites (CA, NM, and TN) were recruited to participate. Patients <18 years who received IV vancomycin in 2013 were identified through pharmacy records, excluding those on IV vancomycin solely for surgical prophylaxis. Trained EIP staff collected medical record data. We created a prescribing quality evaluation pathway using data on infection type, signs, symptoms, penicillin allergy, and AR risk factors. Clinically supported prescribing events were those with a positive culture for a Gram-positive organism with β-lactam resistance or unknown susceptibility; severe penicillin allergy; bone, joint, skin/soft tissue or central nervous system infection; pneumonia with AR risk factors; or events where vancomycin was stopped within 1 day of culture results for an oxacillin or penicillin/ampicillin-susceptible organism. Results Sixty-five patients in 12 hospitals were evaluated. The median age was 7 years (interquartile range [IQR] 4–14), and median hospital stay was 7 days (IQR 3–16). The median vancomycin treatment length was 3 days (IQR 2–6); 41 patients (63%) received ≥3 days. Vancomycin use was clinically supported in 47 patients (72%) and unsupported in 18 (28%) (figure). Most unsupported use was for infections lacking microbiology data and for which vancomycin would not usually be indicated, such as pneumonia without AR risk factors (9/18, 50%). Conclusion The use of IV vancomycin was not supported for >25% of children, indicating opportunities to improve prescribing and reduce unnecessary vancomycin use. Further analysis will utilize this prescribing pathway to evaluate the most recent prevalence survey data to identify areas to target stewardship interventions. ![]()
Disclosures All authors: No reported disclosures.
Collapse
Affiliation(s)
| | - Erin O’Leary
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Joelle Nadle
- California Emerging Infections Program, Oakland, California
| | | | - Daniel Muleta
- Tennessee Department of Health, Nashville, Tennessee
| | - Marion A Kainer
- Communicable and Environmental Diseases and Emergency Preparedness, Tennessee Department of Public Health, Nashville, Tennessee
| | - Lauren Epstein
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Shelley S Magill
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| |
Collapse
|
9
|
Magill SS, O'Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, Wilson LE, Kainer MA, Lynfield R, Greissman S, Ray SM, Beldavs Z, Gross C, Bamberg W, Sievers M, Concannon C, Buhr N, Warnke L, Maloney M, Ocampo V, Brooks J, Oyewumi T, Sharmin S, Richards K, Rainbow J, Samper M, Hancock EB, Leaptrot D, Scalise E, Badrun F, Phelps R, Edwards JR. Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals. N Engl J Med 2018; 379:1732-1744. [PMID: 30380384 PMCID: PMC7978499 DOI: 10.1056/nejmoa1801550] [Citation(s) in RCA: 634] [Impact Index Per Article: 105.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND A point-prevalence survey that was conducted in the United States in 2011 showed that 4% of hospitalized patients had a health care-associated infection. We repeated the survey in 2015 to assess changes in the prevalence of health care-associated infections during a period of national attention to the prevention of such infections. METHODS At Emerging Infections Program sites in 10 states, we recruited up to 25 hospitals in each site area, prioritizing hospitals that had participated in the 2011 survey. Each hospital selected 1 day on which a random sample of patients was identified for assessment. Trained staff reviewed medical records using the 2011 definitions of health care-associated infections. We compared the percentages of patients with health care-associated infections and performed multivariable log-binomial regression modeling to evaluate the association of survey year with the risk of health care-associated infections. RESULTS In 2015, a total of 12,299 patients in 199 hospitals were surveyed, as compared with 11,282 patients in 183 hospitals in 2011. Fewer patients had health care-associated infections in 2015 (394 patients [3.2%; 95% confidence interval {CI}, 2.9 to 3.5]) than in 2011 (452 [4.0%; 95% CI, 3.7 to 4.4]) (P<0.001), largely owing to reductions in the prevalence of surgical-site and urinary tract infections. Pneumonia, gastrointestinal infections (most of which were due to Clostridium difficile [now Clostridioides difficile]), and surgical-site infections were the most common health care-associated infections. Patients' risk of having a health care-associated infection was 16% lower in 2015 than in 2011 (risk ratio, 0.84; 95% CI, 0.74 to 0.95; P=0.005), after adjustment for age, presence of devices, days from admission to survey, and status of being in a large hospital. CONCLUSIONS The prevalence of health care-associated infections was lower in 2015 than in 2011. To continue to make progress in the prevention of such infections, prevention strategies against C. difficile infection and pneumonia should be augmented. (Funded by the Centers for Disease Control and Prevention.).
Collapse
Affiliation(s)
- Shelley S Magill
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Erin O'Leary
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Sarah J Janelle
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Deborah L Thompson
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Ghinwa Dumyati
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Joelle Nadle
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Lucy E Wilson
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Marion A Kainer
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Ruth Lynfield
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Samantha Greissman
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Susan M Ray
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Zintars Beldavs
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Cindy Gross
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Wendy Bamberg
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Marla Sievers
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Cathleen Concannon
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Nicolai Buhr
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Linn Warnke
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Meghan Maloney
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Valerie Ocampo
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Janet Brooks
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Tolulope Oyewumi
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Shamima Sharmin
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Katherine Richards
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Jean Rainbow
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Monika Samper
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Emily B Hancock
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Denise Leaptrot
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Eileen Scalise
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Farzana Badrun
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Ruby Phelps
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| | - Jonathan R Edwards
- From the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, (S.S.M., E.O., C.G., J.B., D.L., E.S., F.B., R.P., J.R.E.), the Department of Medicine, Emory University (S.M.R.), CACI (C.G., J.B., D.L., E.S.), and Eagle Medical Services (F.B.) - all in Atlanta; Colorado Department of Public Health and Environment, Denver (S.J.J., W.B., T.O.); New Mexico Department of Health, Santa Fe (D.L.T., M. Sievers, S.S.), and Presbyterian Healthcare Services (D.L.T.) and University of New Mexico (E.B.H.), Albuquerque; New York Emerging Infections Program and University of Rochester Medical Center, Rochester (G.D., C.C.); California Emerging Infections Program, Oakland (J.N.); Maryland Department of Health, Baltimore (L.E.W., N.B., K.R.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L., L.W., J.R.); Connecticut Emerging Infections Program, New Haven and Hartford (S.G., M.M.); Georgia Emerging Infections Program, Decatur (S.M.R.); and Oregon Health Authority, Portland (Z.B., V.O., M. Samper)
| |
Collapse
|
10
|
Magill SS, Wilson LE, Thompson DL, Ray SM, Nadle J, Lynfield R, Janelle SJ, Kainer MA, Greissman S, Dumyati G, Beldavs ZG, Edwards JR. Reduction in the Prevalence of Healthcare-Associated Infections in U.S. Acute Care Hospitals, 2015 vs 2011. Open Forum Infect Dis 2017. [PMCID: PMC5632177 DOI: 10.1093/ofid/ofx162.116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background A 2011 prevalence survey conducted by CDC and the Emerging Infections Program (EIP) showed that 1 in 25 hospital patients had ≥1 healthcare-associated infection (HAI). We repeated the survey in 2015 to assess changes in HAI prevalence. Methods In EIP sites (CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) hospitals that participated in the 2011 survey were recruited for the 2015 survey. Hospitals selected 1 day from May–September 2015 on which a random patient sample was identified from the morning census. Trained EIP staff reviewed patient medical records using comparable methods and the same National Healthcare Safety Network HAI definitions used in 2011. Proportions of patients with HAIs were compared using chi-square tests; patient characteristics were compared using chi-square or median tests (OpenEpi 3.01, SAS 9.3). Results Data were available from 143 hospitals that participated in both surveys; data from 8954 patients in the 2011 survey were compared with preliminary data from 8833 patients in the 2015 survey. Patient characteristics such as median age, days from admission to survey, and critical care location were similar. Urinary catheter prevalence was lower in 2015 (1,589/8,833, 18.0%) compared with 2011 (2,052/8,954, 22.9%, P < 0.0001), as was central line prevalence (2015: 1,539/8,833, 17.4%, vs. 2011: 1,687/8,954, 18.8%, P = 0.02). The proportion of patients with HAIs was lower in 2015 (284/8,833, 3.2%, 95% confidence interval [CI] 2.9–3.6%) than in 2011 (362/8,954, 4.0%, 95% CI 3.7–4.5%, P = 0.003). Of 309 HAIs in 2015, pneumonia (PNEU) and Clostridium difficileinfections (CDI) were most common (Figure); proportions of patients with PNEU and/or CDI were similar in 2015 (130/8833, 1.5%) and 2011 (133/8954, 1.5%, P = 0.94). A lower proportion of patients had surgical site (SSI) and/or urinary tract infections (UTI) in 2015 (77/8833, 0.9%) vs. 2011 (136/8954, 1.5%, P < 0.001). Conclusion HAI prevalence was significantly lower in 2015 compared with 2011. This is partially explained by fewer SSI and UTI, suggesting national efforts to prevent SSI, reduce catheter use and improve UTI diagnosis are succeeding. By contrast, there was no change in the prevalence of the most common HAIs in 2015, PNEU and CDI, indicating a need for increased prevention efforts in hospitals. Disclosures All authors: No reported disclosures.
Collapse
Affiliation(s)
- Shelley S Magill
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Lucy E Wilson
- Maryland Department of Health and Mental Hygiene, Baltimore, MD
| | - Deborah L Thompson
- Presbyterian Healthcare Services, Albuquerque, New Mexico
- New Mexico Department of Health, Santa Fe, New Mexico
| | - Susan M Ray
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
- Georgia Emerging Infections Program, Decatur, Georgia
| | - Joelle Nadle
- California Emerging Infections Program, Oakland, California
| | | | - Sarah J Janelle
- Colorado Department of Public Health and Environment, Denver, Colorado
| | | | - Samantha Greissman
- Connecticut Emerging Infections Program, Hartford and New Haven, Connecticut
| | - Ghinwa Dumyati
- New York Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York
| | | | - Jonathan R Edwards
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | |
Collapse
|
11
|
Boakari YL, Ferreira JC, Canesin HS, Thompson DL, Lima FS, Pantoja JCF, Meira C. Influence of two ovulation-inducing agents on the pituitary response and follicle blood flow in mares. Theriogenology 2017; 100:95-99. [PMID: 28708540 DOI: 10.1016/j.theriogenology.2017.05.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Revised: 05/24/2017] [Accepted: 05/30/2017] [Indexed: 10/19/2022]
Abstract
The objective of the current study was to evaluate the effects of deslorelin and hCG, two ovulation-inducing therapies, on LH surge and follicle vascularity in mares. Thirty mares were either treated with 1.5 mg IM of deslorelin, 2,500 IU IV of hCG or 2 mL IM of NaCl 0.9% (GnRH, hCG and Saline groups, respectively). Power-flow Doppler examination and blood collection were performed every hour during the first 12 hours after treatment (H0) and every six hours between hours 12 (H12) and 30 (H30) after treatment. Moreover, endpoints were evaluated every hour through the last six hours before ovulation (OV-6 to OV-1). In GnRH group, plasma LH concentration progressively increased (P < 0.001) during the first 6 hours after treatment and remained high (P > 0.1) until OV-1. A significant increase in LH concentrations was first detected (P < 0.05) at 24 hours after treatment in hCG group, while no changes (P > 0.1) on LH levels were found during H0-H30 and between OV-6 and OV-1 in the Saline group. Independent of the treatment, significant variations on the percentage of the follicle wall with Doppler signals were not observed (P > 0.1) throughout the entire experiment. A weak correlation between the preovulatory follicle vascularity and the plasma LH concentration was found in GnRH, hCG and Saline groups (r = +0.29, +0.29 and -0.23, respectively; P ˂ 0.0001). These results described for the first time the immediate and continuous pituitary response to ovulation-inducing therapy with injectable deslorelin. Moreover, spontaneous and induced ovulations were not preceded by an increased follicle vascularity, which differs from previous reports in large animals.
Collapse
Affiliation(s)
- Y L Boakari
- Department of Animal Reproduction and Veterinary Radiology, School of Veterinary Medicine and Animal Science, UNESP, Botucatu, São Paulo, Brazil; Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, United States
| | - J C Ferreira
- Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL, USA; School of Animal Sciences, Louisiana State University Agricultural Center, Baton Rouge, LA, United States.
| | - H S Canesin
- Department of Animal Reproduction and Veterinary Radiology, School of Veterinary Medicine and Animal Science, UNESP, Botucatu, São Paulo, Brazil
| | - D L Thompson
- School of Animal Sciences, Louisiana State University Agricultural Center, Baton Rouge, LA, United States
| | - F S Lima
- Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL, USA
| | - J C F Pantoja
- Department of Animal Reproduction and Veterinary Radiology, School of Veterinary Medicine and Animal Science, UNESP, Botucatu, São Paulo, Brazil
| | - C Meira
- Department of Animal Reproduction and Veterinary Radiology, School of Veterinary Medicine and Animal Science, UNESP, Botucatu, São Paulo, Brazil
| |
Collapse
|
12
|
Freeman CM, Martinez CH, Todt JC, Martinez FJ, Han MK, Thompson DL, McCloskey L, Curtis JL. Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respir Res 2015; 16:94. [PMID: 26243260 PMCID: PMC4531816 DOI: 10.1186/s12931-015-0251-1] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Accepted: 07/08/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Although T cells, especially CD8+, have been implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, their role during acute exacerbations (AE-COPD) is uncertain. METHODS We recruited subjects with COPD and a history of previous AE-COPD and studied them quarterly to collect blood and spontaneously expectorated sputum while stable. During exacerbations (defined by a change in symptoms plus physician diagnosis and altered medications), we collected blood and sputum before administering antibiotics or steroids. We used flow cytometry to identify leukocytes in peripheral blood, plus Luminex® analysis or ELISA to determine levels of inflammatory biomarkers in serum and sputum supernatants. RESULTS Of 33 enrolled subjects, 13 participated in multiple stable visits and had ≥1 AE-COPD visit, yielding 18 events with paired data. Flow cytometric analyses of peripheral blood demonstrated decreased CD4+ and CD8+ T cells during AE-COPD (both absolute and as a percentage of all leukocytes) and significantly increased granulocytes, all of which correlated significantly with serum C-reactive protein (CRP) concentrations. No change was observed in other leukocyte populations during AE-COPD, although the percentage of BDCA-1+ dendritic cells expressing the activation markers CD40 and CD86 increased. During AE-COPD, sICAM-1, sVCAM-1, IL-10, IL-15 and GDF-15 increased in serum, while in sputum supernatants, CRP and TIMP-2 increased and TIMP-1 decreased. CONCLUSIONS The decrease in CD4+ and CD8+ T cells (but not other lymphocyte subsets) in peripheral blood during AE-COPD may indicate T cell extravasation into inflammatory sites or organized lymphoid tissues. GDF-15, a sensitive marker of cardiopulmonary stress that in other settings independently predicts reduced long-term survival, is acutely increased in AE-COPD. These results extend the concept that AE-COPD are systemic inflammatory events to which adaptive immune mechanisms contribute. TRIAL REGISTRATION NCT00281216 , ClinicalTrials.gov.
Collapse
Affiliation(s)
- Christine M Freeman
- Research Service and Pulmonary & Critical Care Medicine Section, Medicine Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, 48105, USA.,Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA
| | - Carlos H Martinez
- Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA
| | - Jill C Todt
- Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA
| | - Fernando J Martinez
- Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA
| | - MeiLan K Han
- Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA
| | - Deborah L Thompson
- Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA
| | - Lisa McCloskey
- Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA
| | - Jeffrey L Curtis
- Pulmonary & Critical Care Medicine Section, Medicine Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, 48105, USA. .,Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, 48109, USA. .,Pulmonary & Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA. .,Department of Veterans Affairs Healthsystem, Pulmonary and Critical Care Medicine Section (506/111G), 2215 Fuller Road, Ann Arbor, MI, 48105-2303, USA.
| |
Collapse
|
13
|
Carothers JT, Nichols MC, Thompson DL. Failure of total hip arthroplasty secondary to infection caused by Brucella abortus and the risk of transmission to operative staff. Am J Orthop (Belle Mead NJ) 2015; 44:E42-E45. [PMID: 25658081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Infection of total knee or hip arthroplasty by Brucella species is a rare complication. We describe the case of a failed hip replacement secondary to infection by Brucella abortus, as well as presentation, treatment course, and 2-year follow-up. In addition, we review the literature for features of periprosthetic Brucella species infections, and we describe the common exposures, clinical presentations, preoperative evaluation, and treatments used in the reported cases. Furthermore, we discuss the risk of transmission to operating room personnel and the appropriate preventative measures to avoid transmission.
Collapse
|
14
|
Magill SS, Edwards JR, Beldavs ZG, Dumyati G, Janelle SJ, Kainer MA, Lynfield R, Nadle J, Neuhauser MM, Ray SM, Richards K, Rodriguez R, Thompson DL, Fridkin SK. Prevalence of antimicrobial use in US acute care hospitals, May-September 2011. JAMA 2014; 312:1438-46. [PMID: 25291579 PMCID: PMC10847977 DOI: 10.1001/jama.2014.12923] [Citation(s) in RCA: 256] [Impact Index Per Article: 25.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Inappropriate antimicrobial drug use is associated with adverse events in hospitalized patients and contributes to the emergence and spread of resistant pathogens. Targeting effective interventions to improve antimicrobial use in the acute care setting requires understanding hospital prescribing practices. OBJECTIVE To determine the prevalence of and describe the rationale for antimicrobial use in participating hospitals. DESIGN, SETTING, AND PARTICIPANTS One-day prevalence surveys were conducted in acute care hospitals in 10 states between May and September 2011. Patients were randomly selected from each hospital's morning census on the survey date. Data collectors reviewed medical records retrospectively to gather data on antimicrobial drugs administered to patients on the survey date and the day prior to the survey date, including reasons for administration, infection sites treated, and whether treated infections began in community or health care settings. MAIN OUTCOMES AND MEASURES Antimicrobial use prevalence, defined as the number of patients receiving antimicrobial drugs at the time of the survey divided by the total number of surveyed patients. RESULTS Of 11,282 patients in 183 hospitals, 5635 (49.9%; 95% CI, 49.0%-50.9%) were administered at least 1 antimicrobial drug; 77.5% (95% CI, 76.6%-78.3%) of antimicrobial drugs were used to treat infections, most commonly involving the lower respiratory tract, urinary tract, or skin and soft tissues, whereas 12.2% (95% CI, 11.5%-12.8%) were given for surgical and 5.9% (95% CI, 5.5%-6.4%) for medical prophylaxis. Of 7641 drugs to treat infections, the most common were parenteral vancomycin (1103, 14.4%; 95% CI, 13.7%-15.2%), ceftriaxone (825, 10.8%; 95% CI, 10.1%-11.5%), piperacillin-tazobactam (788, 10.3%; 95% CI, 9.6%-11.0%), and levofloxacin (694, 9.1%; 95% CI, 8.5%-9.7%). Most drugs administered to treat infections were given for community-onset infections (69.0%; 95% CI, 68.0%-70.1%) and to patients outside critical care units (81.6%; 95% CI, 80.4%-82.7%). The 4 most common treatment antimicrobial drugs overall were also the most common drugs used for both community-onset and health care facility-onset infections and for infections in patients in critical care and noncritical care locations. CONCLUSIONS AND RELEVANCE In this cross-sectional evaluation of antimicrobial use in US hospitals, use of broad-spectrum antimicrobial drugs such as piperacillin-tazobactam and drugs such as vancomycin for resistant pathogens was common, including for treatment of community-onset infections and among patients outside critical care units. Further work is needed to understand the settings and indications for which reducing antimicrobial use can be most effectively and safely accomplished.
Collapse
Affiliation(s)
| | | | | | - Ghinwa Dumyati
- New York - Rochester Emerging Infections Program and University of Rochester Medical Center, Rochester, NY
| | - Sarah J. Janelle
- Colorado Department of Public Health and Environment, Denver, CO
| | | | | | - Joelle Nadle
- California Emerging Infections Program, Oakland, CA
| | - Melinda M. Neuhauser
- Centers for Disease Control and Prevention, Atlanta, GA
- Department of Veterans Affairs Pharmacy Benefits Management Services, Hines, IL
| | - Susan M. Ray
- Georgia Emerging Infections Program and the Atlanta Veterans Affairs Medical Center, Decatur, GA, and Emory University School of Medicine, Atlanta, GA
| | | | | | | | | |
Collapse
|
15
|
Lee WCT, McKibbin SR, Thompson DL, Xue K, Scappucci G, Bishop N, Celler GK, Carroll MS, Simmons MY. Lithography and doping in strained Si towards atomically precise device fabrication. Nanotechnology 2014; 25:145302. [PMID: 24633016 DOI: 10.1088/0957-4484/25/14/145302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
We investigate the ability to introduce strain into atomic-scale silicon device fabrication by performing hydrogen lithography and creating electrically active phosphorus δ-doped silicon on strained silicon-on-insulator (sSOI) substrates. Lithographic patterns were obtained by selectively desorbing hydrogen atoms from a H resist layer adsorbed on a clean, atomically flat sSOI(001) surface with a scanning tunnelling microscope tip operating in ultra-high vacuum. The influence of the tip-to-sample bias on the lithographic process was investigated allowing us to pattern feature-sizes from several microns down to 1.3 nm. In parallel we have investigated the impact of strain on the electrical properties of P:Si δ-doped layers. Despite the presence of strain inducing surface variations in the silicon substrate we still achieve high carrier densities (>1.0 × 10(14) cm(-2)) with mobilities of ∼100 cm(2) V(-1) s(-1). These results open up the possibility of a scanning-probe lithography approach to the fabrication of strained atomic-scale devices in silicon.
Collapse
Affiliation(s)
- W C T Lee
- Australian Research Council Centre of Excellence for Quantum Computation and Communication Technology, School of Physics, University of New South Wales, Sydney, NSW 2052, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370:1198-208. [PMID: 24670166 PMCID: PMC4648343 DOI: 10.1056/nejmoa1306801] [Citation(s) in RCA: 2525] [Impact Index Per Article: 252.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Currently, no single U.S. surveillance system can provide estimates of the burden of all types of health care-associated infections across acute care patient populations. We conducted a prevalence survey in 10 geographically diverse states to determine the prevalence of health care-associated infections in acute care hospitals and generate updated estimates of the national burden of such infections. METHODS We defined health care-associated infections with the use of National Healthcare Safety Network criteria. One-day surveys of randomly selected inpatients were performed in participating hospitals. Hospital personnel collected demographic and limited clinical data. Trained data collectors reviewed medical records retrospectively to identify health care-associated infections active at the time of the survey. Survey data and 2010 Nationwide Inpatient Sample data, stratified according to patient age and length of hospital stay, were used to estimate the total numbers of health care-associated infections and of inpatients with such infections in U.S. acute care hospitals in 2011. RESULTS Surveys were conducted in 183 hospitals. Of 11,282 patients, 452 had 1 or more health care-associated infections (4.0%; 95% confidence interval, 3.7 to 4.4). Of 504 such infections, the most common types were pneumonia (21.8%), surgical-site infections (21.8%), and gastrointestinal infections (17.1%). Clostridium difficile was the most commonly reported pathogen (causing 12.1% of health care-associated infections). Device-associated infections (i.e., central-catheter-associated bloodstream infection, catheter-associated urinary tract infection, and ventilator-associated pneumonia), which have traditionally been the focus of programs to prevent health care-associated infections, accounted for 25.6% of such infections. We estimated that there were 648,000 patients with 721,800 health care-associated infections in U.S. acute care hospitals in 2011. CONCLUSIONS Results of this multistate prevalence survey of health care-associated infections indicate that public health surveillance and prevention activities should continue to address C. difficile infections. As device- and procedure-associated infections decrease, consideration should be given to expanding surveillance and prevention activities to include other health care-associated infections.
Collapse
Affiliation(s)
- Shelley S Magill
- From the Centers for Disease Control and Prevention (S.S.M., J.R.E., L.M.-H., S.K.F.) and Emory University School of Medicine (S.M.R.) - both in Atlanta; Colorado Department of Public Health and Environment, Denver (W.B.); Oregon Public Health Authority, Portland (Z.G.B.); New York-Rochester Emerging Infections Program and University of Rochester, Rochester (G.D.); Tennessee Department of Health, Nashville (M.A.K.); Minnesota Department of Health, St. Paul (R.L.); Connecticut Department of Public Health, Hartford (M.M.); California Emerging Infections Program, Oakland (J.N.); Georgia Emerging Infections Program and the Atlanta Veterans Affairs Medical Center, Decatur (S.M.R.); New Mexico Department of Health, Santa Fe (D.L.T.); and Maryland Department of Health and Mental Hygiene, Baltimore (L.E.W.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Valencia NA, Thompson DL, Mitcham PB. Changes in plasma melanocyte-stimulating hormone, ACTH, prolactin, GH, LH, FSH, and thyroid-stimulating hormone in response to injection of sulpiride, thyrotropin-releasing hormone, or vehicle in insulin-sensitive and -insensitive mares. Domest Anim Endocrinol 2013; 44:204-12. [PMID: 23571008 DOI: 10.1016/j.domaniend.2013.03.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Revised: 03/03/2013] [Accepted: 03/04/2013] [Indexed: 11/29/2022]
Abstract
Six insulin-sensitive and 6 insulin-insensitive mares were used in a replicated 3 by 3 Latin square design to determine the pituitary hormonal responses (compared with vehicle) to sulpiride and thyrotropin-releasing hormone (TRH), 2 compounds commonly used to diagnose pituitary pars intermedia dysfunction (PPID) in horses. Mares were classified as insulin sensitive or insensitive by their previous glucose responses to direct injection of human recombinant insulin. Treatment days were February 25, 2012, and March 10 and 24, 2012. Treatments were sulpiride (racemic mixture, 0.01 mg/kg BW), TRH (0.002 mg/kg BW), and vehicle (saline, 0.01 mL/kg BW) administered intravenously. Blood samples were collected via jugular catheters at -10, 0, 5, 10, 20, 30, 45, 60, 90, and 120 min relative to treatment injection. Plasma ACTH concentrations were variable and were not affected by treatment or insulin sensitivity category. Plasma melanocyte-stimulating hormone (MSH) concentrations responded (P < 0.01) to both sulpiride and TRH injection and were greater (P < 0.05) in insulin-insensitive mares than in sensitive mares. Plasma prolactin concentrations responded (P < 0.01) to both sulpiride and TRH injection, and the response was greater (P < 0.05) for sulpiride; no effect of insulin sensitivity was observed. Plasma thyroid-stimulating hormone (TSH) concentrations responded (P < 0.01) to TRH injection only and were higher (P < 0.05) in insulin-sensitive mares in almost all time periods. Plasma LH and FSH concentrations varied with time (P < 0.05), particularly in the first week of the experiment, but were not affected by treatment or insulin sensitivity category. Plasma GH concentrations were affected (P < 0.05) only by day of treatment. The greater MSH responses to sulpiride and TRH in insulin-insensitive mares were similar to, but not as exaggerated as, those observed by others for PPID horses. In addition, the reduced TSH concentrations in insulin-insensitive mares are consistent with our previous observation of elevated plasma triiodothyronine concentrations in hyperleptinemic horses (later shown to be insulin insensitive as well).
Collapse
Affiliation(s)
- N Arana Valencia
- School of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge, Louisiana 70803-4210, USA
| | | | | |
Collapse
|
18
|
Thompson DL, Baumbach J, Jungk J, Sewell CM, Smelser C, Landen M. Does outpatient laboratory testing represent influenza burden and distribution in a rural state? Influenza Other Respir Viruses 2013; 7:686-93. [PMID: 23496769 PMCID: PMC5781201 DOI: 10.1111/irv.12097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/18/2013] [Indexed: 11/28/2022] Open
Abstract
Background Laboratory testing results are often used to monitor influenza illness in populations, but results may not be representative of illness burden and distribution, especially in populations that are geographically, socioeconomically, and racially/ethnically diverse. Objectives Descriptive epidemiology and chi‐square analyses using demographic, geographic, and medical condition prevalence comparisons were employed to assess whether a group of individuals with outpatient laboratory‐confirmed influenza illness during September–November 2009 represented the burden and distribution of influenza illness in New Mexico (NM). Patients/Methods The outpatient group was identified via random selection from those with positive influenza tests at NM laboratories. Comparison groups included those with laboratory‐confirmed H1N1‐related influenza hospitalization and death identified via prospective active statewide surveillance, those with self‐reported influenza‐like illness (ILI) identified through random digit dialing, and the NM population. Results This analysis included 334 individuals with outpatient laboratory‐confirmed influenza, 888 individuals with laboratory‐confirmed H1N1‐related hospitalization, 39 individuals with laboratory‐confirmed H1N1‐related death, 334 individuals with ILI, and NM population data (N = 2 036 112). The outpatient laboratory‐confirmed group had a different distribution of demographic and geographic factors, as well as prevalence of certain medical conditions as compared to the groups of laboratory‐confirmed H1N1‐related hospitalization and death, the ILI group, and the NM population. Conclusions The outpatient laboratory‐confirmed group may reflect provider testing practices and potentially healthcare‐seeking behavior and access to care, rather than influenza burden and distribution in NM during the H1N1 pandemic.
Collapse
|
19
|
Thompson DL, Makvandi M, Baumbach J. Validation of central line-associated bloodstream infection data in a voluntary reporting state: New Mexico. Am J Infect Control 2013; 41:122-5. [PMID: 23040607 DOI: 10.1016/j.ajic.2012.03.039] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2012] [Revised: 03/28/2012] [Accepted: 03/28/2012] [Indexed: 10/27/2022]
Abstract
BACKGROUND In New Mexico, voluntary submission of central line-associated bloodstream infection (CLABSI) surveillance data via the National Healthcare Safety Network (NHSN) began in July 2008. Validation of CLABSI data is necessary to ensure quality, accuracy, and reliability of surveillance efforts. METHODS We conducted a retrospective medical record review of 123 individuals with positive blood cultures who were admitted to adult intensive care units (ICU) at 6 New Mexico hospitals between November 2009 and March 2010. Blinded reviews were conducted independently by pairs of reviewers using standardized data collection instruments. Findings were compared between reviewers and with NHSN data. Discordant cases were reviewed and reconciled with hospital infection preventionists. RESULTS Initially, 118 individuals were identified for medical record review. Seven ICU CLABSI events were identified by the reviewers. Data submitted to the NHSN revealed 8 ICU CLABSI events, 5 of which had not been identified for medical record review and 3 of which had been determined by reviewers to not be ICU CLABSI cases. Comparison of final case determinations for all 123 individuals with NHSN data resulted in a sensitivity of 66.7%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 96.5% for ICU CLABSI surveillance. CONCLUSIONS There is need for ongoing quality improvement and validation processes to ensure accurate NHSN data.
Collapse
|
20
|
Bank LM, Bianchi LM, Ebisu F, Lerman-Sinkoff D, Smiley EC, Shen YC, Ramamurthy P, Thompson DL, Roth TM, Beck CR, Flynn M, Teller RS, Feng L, Llewellyn GN, Holmes B, Sharples C, Coutinho-Budd J, Linn SA, Chervenak AP, Dolan DF, Benson J, Kanicki A, Martin CA, Altschuler R, Koch AE, Koch AE, Jewett EM, Germiller JA, Barald KF. Macrophage migration inhibitory factor acts as a neurotrophin in the developing inner ear. Development 2013; 139:4666-74. [PMID: 23172918 DOI: 10.1242/dev.066647] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
This study is the first to demonstrate that macrophage migration inhibitory factor (MIF), an immune system 'inflammatory' cytokine that is released by the developing otocyst, plays a role in regulating early innervation of the mouse and chick inner ear. We demonstrate that MIF is a major bioactive component of the previously uncharacterized otocyst-derived factor, which directs initial neurite outgrowth from the statoacoustic ganglion (SAG) to the developing inner ear. Recombinant MIF acts as a neurotrophin in promoting both SAG directional neurite outgrowth and neuronal survival and is expressed in both the developing and mature inner ear of chick and mouse. A MIF receptor, CD74, is found on both embryonic SAG neurons and adult mouse spiral ganglion neurons. Mif knockout mice are hearing impaired and demonstrate altered innervation to the organ of Corti, as well as fewer sensory hair cells. Furthermore, mouse embryonic stem cells become neuron-like when exposed to picomolar levels of MIF, suggesting the general importance of this cytokine in neural development.
Collapse
Affiliation(s)
- Lisa M Bank
- Department of Cell and Developmental Biology, University of Michigan Medical School, 3728 BSRB 109, Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Bank LM, Bianchi LM, Ebisu F, Lerman-Sinkoff D, Smiley EC, Shen YC, Ramamurthy P, Thompson DL, Roth TM, Beck CR, Flynn M, Teller RS, Feng L, Llewellyn GN, Holmes B, Sharples C, Coutinho-Budd J, Linn SA, Chervenak AP, Dolan DF, Benson J, Kanicki A, Martin CA, Altschuler R, Koch AE, Jewett EM, Germiller JA, Barald KF. Macrophage migration inhibitory factor acts as a neurotrophin in the developing inner ear. Development 2013. [DOI: 10.1242/dev.092486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
22
|
Berndtson WE, Squires EL, Thompson DL. Spermatogenesis, testicular composition and the concentration of testosterone in the equine testis as influenced by season. Theriogenology 2012; 20:449-57. [PMID: 16725860 DOI: 10.1016/0093-691x(83)90204-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/1983] [Accepted: 08/17/1983] [Indexed: 11/29/2022]
Abstract
The influence of season on spermatogenesis, testicular composition and the concentration of testosterone in the equine testis was evaluated using testes from 45 stallions. Testes were obtained through a commercial abbatoir during September, December-January, March and July. The weights of the testes, the tunica albuginea and testicular parenchyma and the proportion of the testicular parenchyma occupied by seminiferous tubules or interstitial tissue were similar during each season. How ever, diameter of the seminiferous tubules was greater in July than during other months of the study. In addition, the concentration of testosterone within the testicular parenchyma was twice as great during July as during the fall and winter, and this period of peak testicular testosterone concentrations was associated with spermatozoal production rates, which were 65% greater than those observed in September.
Collapse
Affiliation(s)
- W E Berndtson
- Department of Animal Sciences University of New Hampshire Durham, New Hampshire 03824 UK
| | | | | |
Collapse
|
23
|
Shen YC, Thompson DL, Kuah MK, Wong KL, Wu KL, Linn SA, Jewett EM, Shu-Chien AC, Barald KF. The cytokine macrophage migration inhibitory factor (MIF) acts as a neurotrophin in the developing inner ear of the zebrafish, Danio rerio. Dev Biol 2011; 363:84-94. [PMID: 22210003 DOI: 10.1016/j.ydbio.2011.12.023] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2011] [Revised: 04/06/2011] [Accepted: 12/21/2011] [Indexed: 10/14/2022]
Abstract
Macrophage migration inhibitory factor (MIF) plays versatile roles in the immune system. MIF is also widely expressed during embryonic development, particularly in the nervous system, although its roles in neural development are only beginning to be understood. Evidence from frogs, mice and zebrafish suggests that MIF has a major role as a neurotrophin in the early development of sensory systems, including the auditory system. Here we show that the zebrafish mif pathway is required for both sensory hair cell (HC) and sensory neuronal cell survival in the ear, for HC differentiation, semicircular canal formation, statoacoustic ganglion (SAG) development, and lateral line HC differentiation. This is consistent with our findings that MIF is expressed in the developing mammalian and avian auditory systems and promotes mouse and chick SAG neurite outgrowth and neuronal survival, demonstrating key instructional roles for MIF in vertebrate otic development.
Collapse
Affiliation(s)
- Yu-chi Shen
- Department of Cell and Developmental Biology, Medical School, University of Michigan, Ann Arbor, MI, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Thompson DL, Jungk J, Hancock E, Smelser C, Landen M, Nichols M, Selvage D, Baumbach J, Sewell M. Risk factors for 2009 pandemic influenza A (H1N1)-related hospitalization and death among racial/ethnic groups in New Mexico. Am J Public Health 2011; 101:1776-84. [PMID: 21778495 PMCID: PMC3154223 DOI: 10.2105/ajph.2011.300223] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/11/2011] [Indexed: 11/04/2022]
Abstract
OBJECTIVES We assessed risk factors for 2009 pandemic influenza A (H1N1)-related hospitalization, mechanical ventilation, and death among New Mexico residents. METHODS We calculated population rate ratios using Poisson regression to analyze risk factors for H1N1-related hospitalization. We performed a cross-sectional analysis of hospitalizations during September 14, 2009 through January 13, 2010, using logistic regression to assess risk factors for mechanical ventilation and death among those hospitalized. RESULTS During the study period, 926 laboratory-confirmed H1N1-related hospitalizations were identified. H1N1-related hospitalization was significantly higher among American Indians (risk ratio [RR] = 2.6; 95% confidence interval [CI] = 2.2, 3.2), Blacks (RR = 1.7; 95% CI = 1.2, 2.4), and Hispanics (RR = 1.8; 95% CI = 1.5, 2.0) than it was among non-Hispanic Whites, and also was higher among persons of younger age and lower household income. Mechanical ventilation was significantly associated with age 25 years and older, obesity, and lack of or delayed antiviral treatment. Death was significantly associated with male gender, cancer during the previous 12 months, and liver disorder. CONCLUSIONS This analysis supports recent national efforts to include American Indian/Alaska Native race as a group at high risk for complications of influenza with respect to vaccination and antiviral treatment recommendations.
Collapse
|
25
|
Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, Young VB, Toews GB, Curtis JL, Sundaram B, Martinez FJ, Huffnagle GB. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011; 6:e16384. [PMID: 21364979 PMCID: PMC3043049 DOI: 10.1371/journal.pone.0016384] [Citation(s) in RCA: 648] [Impact Index Per Article: 49.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2010] [Accepted: 12/14/2010] [Indexed: 12/16/2022] Open
Abstract
Although culture-independent techniques have shown that the lungs are not sterile, little is known about the lung microbiome in chronic obstructive pulmonary disease (COPD). We used pyrosequencing of 16S amplicons to analyze the lung microbiome in two ways: first, using bronchoalveolar lavage (BAL) to sample the distal bronchi and air-spaces; and second, by examining multiple discrete tissue sites in the lungs of six subjects removed at the time of transplantation. We performed BAL on three never-smokers (NS) with normal spirometry, seven smokers with normal spirometry ("healthy smokers", HS), and four subjects with COPD (CS). Bacterial 16 s sequences were found in all subjects, without significant quantitative differences between groups. Both taxonomy-based and taxonomy-independent approaches disclosed heterogeneity in the bacterial communities between HS subjects that was similar to that seen in healthy NS and two mild COPD patients. The moderate and severe COPD patients had very limited community diversity, which was also noted in 28% of the healthy subjects. Both approaches revealed extensive membership overlap between the bacterial communities of the three study groups. No genera were common within a group but unique across groups. Our data suggests the existence of a core pulmonary bacterial microbiome that includes Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Haemophilus, Veillonella, and Porphyromonas. Most strikingly, there were significant micro-anatomic differences in bacterial communities within the same lung of subjects with advanced COPD. These studies are further demonstration of the pulmonary microbiome and highlight global and micro-anatomic changes in these bacterial communities in severe COPD patients.
Collapse
|
26
|
|
27
|
Abstract
We determined the validity of the Nike+ device for estimating speed, distance, and energy expenditure (EE) during walking and running. Twenty trained individuals performed a maximal oxygen uptake test and underwent anthropometric and body composition testing. Each participant was outfitted with a Nike+ sensor inserted into the shoe and an Apple iPod nano. They performed eight 6-min stages on the treadmill, including level walking at 55, 82, and 107 m x min(-1), inclined walking (82 m x min(-1)) at 5 and 10% grades, and level running at 134, 161, and 188 m x min(-1). Speed was measured using a tachometer and EE was measured by indirect calorimetry. Results showed that the Nike+ device overestimated the speed of level walking at 55 m x min(-1) by 20%, underestimated the speed of level walking at 107 m x min(-1) by 12%, but closely estimated the speed of level walking at 82 m x min(-1), and level running at all speeds (p<0.05). Similar results were found for distance. The Nike+ device overestimated the EE of level walking by 18-37%, but closely estimated the EE of level running (p<0.05). In conclusion the Nike+ in-shoe device provided reasonable estimates of speed and distance during level running at the three speeds tested in this study. However, it overestimated EE during level walking and it did not detect the increased cost of inclined locomotion.
Collapse
Affiliation(s)
- N A Kane
- University of Tennessee, Exercise, Sport, and Leisure Studies, Knoxville, 37996, USA
| | | | | | | | | | | |
Collapse
|
28
|
Shen YC, Jeyabalan AK, Wu KL, Hunker KL, Kohrman DC, Thompson DL, Liu D, Barald KF. The transmembrane inner ear (tmie) gene contributes to vestibular and lateral line development and function in the zebrafish (Danio rerio). Dev Dyn 2008; 237:941-52. [PMID: 18330929 DOI: 10.1002/dvdy.21486] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
The inner ear is a complex organ containing sensory tissue, including hair cells, the development of which is not well understood. Our long-term goal is to discover genes critical for the correct formation and function of the inner ear and its sensory tissue. A novel gene, transmembrane inner ear (Tmie), was found to cause hearing-related disorders when defective in mice and humans. A homologous tmie gene in zebrafish was cloned and its expression characterized between 24 and 51 hours post-fertilization. Embryos injected with morpholinos (MO) directed against tmie exhibited circling swimming behavior (approximately 37%), phenocopying mice with Tmie mutations; semicircular canal formation was disrupted, hair cell numbers were reduced, and maturation of electrically active lateral line neuromasts was delayed. As in the mouse, tmie appears to be required for inner ear development and function in the zebrafish and for hair cell maturation in the vestibular and lateral line systems as well.
Collapse
Affiliation(s)
- Yu-Chi Shen
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, Michigan 48109-2200, USA
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Storer WA, Thompson DL, Waller CA, Cartmill JA. Hormonal patterns in normal and hyperleptinemic mares in response to three common feeding-housing regimens1. J Anim Sci 2007; 85:2873-81. [PMID: 17591706 DOI: 10.2527/jas.2007-0182] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
We previously reported that a rise in plasma leptin concentrations followed the rise in insulin and glucose in meal-fed horses, whereas horses maintained on pasture had little fluctuations in hormonal patterns. We have also described a hyperleptinemic-hyperinsulinemic condition that occurs in about 30% of our light horse mares of high body condition maintained on pasture. The present experiment was designed to 1) study the effect of 3 common feeding-housing regimens on leptin and other metabolic hormones in mares and 2) determine whether the hyperleptinemic condition interacted with these regimens. Six light horse mares with high body condition (average score = 7) were assigned to 2 simultaneous 3 x 3 Latin squares, 1 with normal mares (leptin = 0.1 to 6 ng/mL) and 1 with mares displaying hyperleptinemia (>10 ng/mL). Three feeding-housing regimens were compared: ad libitum pasture, ad libitum native grass hay in an outdoor paddock, and single morning feedings of a pelleted concentrate and hay at 0700 in a barn. Five days of acclimation to the feeding regimens were followed by a 36-h period of hourly blood collection to characterize the hormonal characteristics. Leptin concentrations were elevated (P < 0.001) in mares predetermined to be hyperleptinemic compared with normal mares, regardless of the feeding regimen. Leptin was greatest (P < 0.01) in mares on pasture and least in mares fed hay. Variations over time (P < 0.01) were present for all hormones and metabolites studied. Glucose and insulin concentrations were greatest (P < 0.01) in mares on pasture, with meal-fed mares exhibiting an immediate rise in plasma concentrations of both after feeding. Mares on hay had low and constant concentrations of glucose, insulin, and leptin, with no apparent fluctuations. Cortisol, prolactin, and IGF-I did not differ with leptin status, whereas GH differed due to feeding-housing regimen (P < 0.02); there was also an interaction of leptin status and feeding-housing regimen for GH concentrations (P = 0.094). It was concluded that 1) estimates of hormonal secretion in horses based on frequent sampling, depending upon the hormone in question, can be profoundly affected by the feeding-housing regimens, and 2) the hyperleptinemic condition persists under differing conditions of feeding-housing.
Collapse
Affiliation(s)
- W A Storer
- School of Animal Sciences, Louisiana Agriculture Experiment Station, Louisiana State University Agricultural Center, Baton Rouge 70803, USA
| | | | | | | |
Collapse
|
30
|
Diallo EM, Wilhelm KG, Thompson DL, Koenig RJ. Variable RXR requirements for thyroid hormone responsiveness of endogenous genes. Mol Cell Endocrinol 2007; 264:149-56. [PMID: 17161906 PMCID: PMC1828278 DOI: 10.1016/j.mce.2006.11.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2006] [Revised: 10/31/2006] [Accepted: 11/07/2006] [Indexed: 11/30/2022]
Abstract
Thyroid hormone receptors heterodimerize with retinoid X receptors in vitro and it is widely assumed that these heterodimers mediate the T3 induction of target genes. However, the importance of RXR for the T3 induction of endogenous genes has not been assessed. We used cDNA microarrays to identify 54 genes induced by T3 in Neuro2a cells that express thyroid hormone receptor beta. RNA interference-mediated knock down of endogenous RXRs showed that these genes vary from being highly dependent on RXR for T3 induction to being independent of RXR. Thus, the availability of RXR may differentially regulate the T3 induction of subsets of genes within a cell. Furthermore, coregulatory proteins that preferentially interact with TR homodimers or RXR-TR heterodimers may further expand the range of T3 response for genes within the same cell.
Collapse
Affiliation(s)
| | | | | | - Ronald J. Koenig
- *Corresponding Author: Ronald J. Koenig, University of Michigan, 5560 MSRB-II, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-0678, Telephone: 734-763-3056, Fax: 734-936-6684,
| |
Collapse
|
31
|
Cartmill JA, Thompson DL, Del Vecchio RP, Storer WA, Crowley JC. Leptin secretion in horses: effects of dexamethasone, gender, and testosterone. Domest Anim Endocrinol 2006; 31:197-210. [PMID: 16305819 DOI: 10.1016/j.domaniend.2005.10.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2005] [Revised: 10/23/2005] [Accepted: 10/24/2005] [Indexed: 10/25/2022]
Abstract
Five experiments were performed to evaluate the effects of dexamethasone (DEX), gender, and testosterone on plasma leptin concentrations in horses. In experiment 1, plasma leptin, insulin, glucose, and IGF-1 concentrations were increased (P < 0.01) in stallions following five daily injections of DEX (125 microg/kg BW). In experiment 2, leptin concentrations increased (P < 0.01) in mares, geldings, and stallions following a single injection of DEX, and the response was greater (P < 0.01) in mares and geldings than in stallions. The gender effect was confounded by differences in body condition scores and diet; however, based on stepwise regression analysis, both BCS and gender were significant sources of variation in the best fit model for pre-DEX leptin concentrations (R(2) = 0.65) and for maximum leptin response to DEX (R(2) = 0.75). In experiment 3, in which mares and stallions were pair-matched based on age and body condition and fed similar diets, mares again had higher (P < 0.01) leptin concentrations than stallions after DEX treatment as used in experiment 2. In experiment 4, there was no difference (P > 0.1) in plasma leptin response in mares following four single-injection doses of DEX from 15.6 to 125 microg/kg BW. In experiment 5, treatment of mares with testosterone propionate every other day for 5 days did not alter (P > 0.1) plasma leptin concentrations or the leptin response to DEX. In conclusion, multiple injections of DEX increase leptin concentrations in stallions, as does a single injection in mares (as low as 15.6 microg/kg BW), geldings and stallions. The greater leptin levels observed in mares and geldings relative to stallions were due partially to their greater body condition and partially to the presence of hyperleptinemic individuals; however, even after accounting for body condition and diet, mares still had greater leptin concentrations than stallions after DEX administration. Elevation of testosterone levels in mares for approximately 10 days did not alter leptin concentrations in mares.
Collapse
Affiliation(s)
- J A Cartmill
- Department of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge, LA 70803, USA
| | | | | | | | | |
Collapse
|
32
|
Cartmill JA, Thompson DL, Storer WA, Crowley JC, Huff NK, Waller CA. Effect of dexamethasone, feeding time, and insulin infusion on leptin concentrations in stallions. J Anim Sci 2006; 83:1875-81. [PMID: 16024707 DOI: 10.2527/2005.8381875x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Three experiments tested the hypotheses that daily cortisol rhythm, feeding time, and/or insulin infusion affect(s) leptin secretion in stallions. Ten mature stallions received ad libitum hay and water and were fed a grain concentrate once daily at 0700. In Exp. 1, stallions received either a single injection of dexamethasone (125 microg/kg BW i.m.; n = 5) or vehicle (controls; n = 5) at 0700 on d -1. Starting 24 h later, blood samples were collected every 2 h for 36 h via jugular venipuncture. Cortisol in control stallions varied (P < 0.01) with time, with a morning peak and evening nadir; dexamethasone suppressed (P < 0.01) cortisol concentrations. Leptin and insulin were greater (P < 0.01) in the treated stallions, as was the insulin response to feeding (P < 0.01). Leptin in control stallions varied (P < 0.01) in a diurnal pattern, peaking approximately 10 h after onset of eating. This pattern of leptin secretion was similar, although of greater magnitude (P < 0.01), in treated stallions. In Exp. 2, five stallions were fed the concentrate portion of their diet daily at 0700 and five were switched to feeding at 1900. After 14 d on these regimens, blood samples were collected every 4 h for 48 h and then twice daily for 5 d. Cortisol varied diurnally (P = 0.02) and was not altered (P = 0.21) by feeding time. Insulin and leptin increased (P < 0.01) after feeding, and the peaks in insulin and leptin were shifted 12 h by feeding at 1900. In Exp. 3, six stallions were used in two 3 x 3 Latin square experiments. Treatments were 1) normal daily meal at 0700; 2) no feed for 24 h; and 3) no feed and a bolus injection of insulin (0.4 mIU/kg BW i.v.) followed by infusion of insulin (1.2 mIU.kg BW(-1).min(-1)) for 180 min, which was gradually decreased to 0 by 240 min; sufficient glucose was infused to maintain euglycemia. Plasma insulin increased (P < 0.01) in stallions when they were meal-fed (to approximately 150 microIU/mL) or infused with insulin and glucose (to approximately 75 microIU/mL), but insulin remained low (10 microIU/mL or less) when they were not fed. The increases in insulin were paralleled by gradual increases (P < 0.01) in leptin concentrations 3 to 4 h later in stallions fed or infused with insulin and glucose. When stallions were not fed, leptin concentrations remained low. These results demonstrate that feeding time, and more specifically the insulin increase associated with a meal, not cortisol rhythm, drives the postprandial increase in plasma leptin concentrations in horses.
Collapse
Affiliation(s)
- J A Cartmill
- Department of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge, 70803, USA
| | | | | | | | | | | |
Collapse
|
33
|
Moore EE, Bendele AM, Thompson DL, Littau A, Waggie KS, Reardon B, Ellsworth JL. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005; 13:623-31. [PMID: 15896984 DOI: 10.1016/j.joca.2005.03.003] [Citation(s) in RCA: 226] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2004] [Accepted: 03/02/2005] [Indexed: 02/08/2023]
Abstract
OBJECTIVE Osteoarthritis (OA) is the most common form of arthritis and a primary cause of disability, however, there are no treatments that can slow disease progression or repair damaged joint cartilage. Fibroblast growth factor-18 (FGF18) has been reported to have significant anabolic effects on cartilage. We therefore examined its effects on repair of cartilage damage in a rat meniscal tear model of OA. DESIGN Surgical damage to the meniscus in rats leads to joint instability and significant damage to the articular cartilage at 3 weeks post-surgery. At this time, animals received bi-weekly intra-articular injections of FGF18 for 3 weeks, and the knee joints were then harvested for histologic examination. RESULTS FGF18-induced dose-dependent increases in cartilage thickness of the tibial plateau, due to new cartilage formation at the articular surface and the joint periphery. The generation of new cartilage resulted in significant reductions in cartilage degeneration scores. The highest dose of FGF18 also induced an increase in chondrophyte size and increased remodeling of the subchondral bone. CONCLUSIONS The results of this study demonstrate that FGF18 can stimulate repair of damaged cartilage in a setting of rapidly progressive OA in rats.
Collapse
Affiliation(s)
- E E Moore
- ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Diallo EM, Thompson DL, Koenig RJ. A method for efficient production of recombinant thyroid hormone receptors reveals that receptor homodimer–DNA binding is enhanced by the coactivator TIF2. Protein Expr Purif 2005; 40:292-8. [PMID: 15766871 DOI: 10.1016/j.pep.2005.01.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2004] [Revised: 01/03/2005] [Indexed: 11/19/2022]
Abstract
Thyroid hormone receptors (TRs) are ligand-activated transcription factors that mediate the biological effects of thyroid hormone (T3) by binding to thyroid hormone response elements (TREs), typically located in the promoter regions of T3-responsive genes. It is generally held that T3-induced gene activation is mediated by retinoid X receptor (RXR)-TR heterodimers. Although TR homodimers can bind to some TREs, T3 destabilizes this interaction, calling into question the ability of TR to activate transcription in the absence of RXR. TR-DNA binding has been difficult to study in vitro because mammalian TRs are notoriously difficult to produce in Escherichia coli. We considered that this may be due to codon bias. Therefore, we produced TRbeta1 in E. coli Rosetta 2(DE3) which contains a plasmid that overexpresses the tRNAs corresponding to the seven rarest E. coli codons. This resulted in an improved yield of full-length TRbeta1, which we then used in electrophoretic mobility shift assays. We found the coactivator TIF2 greatly enhances binding of T3-occupied TRs to a subset of TREs, suggesting TRs may activate transcription from these TREs in an RXR-independent manner.
Collapse
Affiliation(s)
- Ericka M Diallo
- Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0678, USA
| | | | | |
Collapse
|
35
|
Thompson DL, Douglas JM, Foster M, Hagensee ME, Diguiseppi C, Barón AE, Cameron JE, Spencer TC, Zenilman J, Malotte CK, Bolan G, Kamb ML, Peterman TA. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 2004; 190:1563-74. [PMID: 15478060 DOI: 10.1086/423817] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2003] [Accepted: 04/02/2004] [Indexed: 11/04/2022] Open
Abstract
BACKGROUND The study sought to characterize the seroprevalence, seropersistence, and seroincidence of human papillomavirus (HPV)-16 antibody, as well as the behavioral risk factors for HPV-16 seropositivity. METHODS Serologic data at baseline and at 6- and 12-month follow-up visits were used to examine the seroprevalence, seropersistence, and seroincidence of HPV-16 antibody in 1595 patients attending United States clinics treating sexually transmitted disease. Testing for antibody to HPV-16 was performed by capture enzyme-linked immunosorbent assay (ELISA) using viruslike particles. RESULTS The seroprevalence of HPV-16 antibody was 24.5% overall and was higher in women than in men (30.2% vs. 18.7%, respectively). In those who were HPV-16 seropositive at baseline, antibody response persisted to 12 months in 72.5% of women and in 45.6% of men. The seroincidence of HPV-16 antibody was 20.2/100 person-years (py) overall, 25.4/100 py in women, and 15.7/100 py in men. In multivariate analysis, the seroprevalence of HPV-16 antibody was significantly associated with female sex, age >20 years, and the number of episodes of sex with occasional partners during the preceding 3 months, whereas the seroincidence of HPV-16 antibody was significantly associated with female sex, age >20 years, baseline negative ELISA result greater than the median value, and the number of episodes of unprotected sex with occasional partners during the preceding 3 months. CONCLUSION Sex- and age-related differences in both the seropositivity and seroincidence of HPV-16 antibody persisted after adjustment for behavioral and sociodemographic risk factors, and behavioral risk factors during the preceding 3 months were stronger predictors of the seroprevalence and seroincidence of HPV-16 antibody than was lifetime sexual behavior.
Collapse
Affiliation(s)
- Deborah L Thompson
- University of Colorado Health Sciences Center and Denver Public Health Department, Denver Health Medical Center, Denver, Colorado, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Abstract
Electronic pedometers are accurate for assessing steps taken while walking in normal weight adults but the accuracy of these devices has not been tested in overweight and obese men and women. The primary purpose of this study was to assess the accuracy of an electronic pedometer for measuring steps taken at various walking speeds in groups of adults with variations in body mass index (BMI). The secondary purpose was to determine if the manufacturer recommended position is the best placement position for overweight and obese adults. Participants were categorized into one of three BMI categories identified by the World Health Organization: normal (N = 25; < 25 kg x m(-2)), overweight (N = 24; 25 - 29.9 kg x m(-2)), or obese (N = 17; > or = 30 kg x m(-2)). Participants walked on a treadmill for 3 min at 54, 67, 80, 94, and 107 m x min(-1) for a total of 15 min. During the treadmill walking, three electronic pedometers tallied steps taken. The pedometers were placed at the waist level, one on the anterior mid-line of the thigh (front; manufacturer recommended placement), one on the mid-axillary line (side), and one on the posterior mid-line of the thigh (back). Concurrently, a researcher counted steps using a hand-tally counter. Category of BMI did not affect the accuracy of the pedometer at any walking speed (54 m x min(-1), p = 0.991; 67 m x min(-1), p = 0.556; 80 m x min(-1), p = 0.591; 94 m x min(-1), p = 0.426; 107 m x min(-1), p = 0.869). At 54 m x min(-1), the front, side, and back pedometers significantly underestimated hand-tally counted steps by 20 % (p < 0.001), 33 % (p < 0.001), and 26 % (p < 0.001), respectively. At 67 m x min(-1) the front, side, and back pedometers significantly underestimated hand-tally counted steps by 7 % (p = 0.027), 13 % (p < 0.001), 11 % (p = 0.002), respectively. The steps recorded by the electronic pedometers placed at the front, side and back of the waist were not significantly different than steps counted by the hand-tally counter at speeds of 80 m x min(-1) and higher for all subjects combined. An electronic pedometer accurately quantified steps walked at speeds of 80 m x min(-1) or faster in persons with a normal BMI and those classified as overweight or obese. The placement of the pedometer on the front, side or back of the waistband did not affect accuracy of the pedometer for counting steps.
Collapse
Affiliation(s)
- A M Swartz
- Department of Health, Safety and Exercise Science, The University of Tennessee, Knoxville, 37996-2700, USA.
| | | | | | | | | |
Collapse
|
38
|
Pinto CRF, Paccamonti DL, Eilts BE, Venugopal CS, Short CR, Gentry LR, Thompson DL, Godke RA. Concentrations of nitric oxide in equine preovulatory follicles before and after administration of human chorionic gonadotropin. Theriogenology 2003; 60:819-27. [PMID: 12935860 DOI: 10.1016/s0093-691x(03)00096-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In the present study, follicular fluids of estrous mares treated with saline solution (Control) or nitric oxide synthase (NOS) inhibitors were analyzed for nitric oxide (NO), estradiol-17beta (E2) and progesterone (P4) concentrations before and 36h after administration of human chorionic gonadotropin (hCG). Follicular fluids obtained before (0h) hCG administration from control mares had lower concentrations of NO than those obtained 36h after administration of hCG (58.3+/-17.8 micromol versus 340.4+/-57.7 micromol; P<0.05). A similar pattern was also noted for intrafollicular P4 in control mares, which had lower concentrations of intrafollicular P4 before hCG than 36h post-hCG administration (P<0.05). As expected, E2 concentrations of control follicles sampled before hCG administration were higher than those sampled 36h post-hCG administration (P<0.05). However, the E2 concentrations in follicles of mares treated with the NOS inhibitors N(omega)-nitro-L-arginine methyl ester (L-NAME) or aminoguanidine (AG) did not decrease after hCG administration, unlike those in control mares (P>0.10). In addition, mares treated with NOS inhibitors had lower intrafollicular concentrations of NO and P4 than control mares, both before and after hCG administration (P<0.05). Increased intrafollicular concentrations of NO in control, hCG-stimulated mares provide evidence for the presence of an NO-generating system in the equine preovulatory follicle that is likely upregulated following administration of hCG.
Collapse
Affiliation(s)
- C R F Pinto
- Equine Health Studies Program, Department of Comparative Biomedical Sciences, Louisiana State University and Agricultural Center, Baton Rouge, LA 70803, USA.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Cartmill JA, Thompson DL, Storer WA, Gentry LR, Huff NK. Endocrine responses in mares and geldings with high body condition scores grouped by high vs. low resting leptin concentrations. J Anim Sci 2003; 81:2311-21. [PMID: 12968707 DOI: 10.2527/2003.8192311x] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Previous observations from this laboratory indicated that horses with high BCS could have resting plasma leptin concentrations ranging from low (1 to 5 ng/mL) to very high (10 to 50 ng/mL). To study the possible interactions of leptin secretion with other endocrine systems, BCS and plasma leptin concentrations were measured on 36 mares and 18 geldings. From mares and geldings that had a mean BCS of at least 7.5, five with the lowest (low leptin) and five with the highest (high leptin) leptin concentrations were selected. Jugular blood samples were collected twice daily for 3 d from the 20 selected horses to determine average resting hormone concentrations. Over the next 12 d, glucose infusion, injection of thyrotropin-releasing hormone (TRH), exercise, and dexamethasone treatment were used to perturb various hormonal systems. By design, horses selected for high leptin had greater (P < 0.0001) leptin concentrations than horses selected for low leptin (14.1 vs. 2.8 +/- 0.92 ng/mL, respectively). In addition, mares had greater (P = 0.008) leptin concentrations than geldings. Horses selected for high leptin had lower (P = 0.027) concentrations of GH but higher (P = 0.0005) concentrations of insulin and thriiodothyronine (T3) than those selected for low leptin. Mares had greater (P = 0.0006) concentrations of cortisol than geldings. There was no difference (P > 0.10) in concentrations of IGF-1, prolactin, or thyroid-stimulating hormone (TSH). Horses selected for high leptin had a greater (P = 0.0365) insulin response to i.v. glucose infusion than horses selected for low leptin. Mares had a greater (P = 0.0006) TSH response and tended (P = 0.088) to have a greater prolactin response to TRH than geldings; the T3 response was greater (P = 0.047) in horses selected for high leptin. The leptin (P = 0.0057), insulin (P < 0.0001), and glucose (P = 0.0063) responses to dexamethasone were greater in horses selected for high leptin than in those selected for low leptin. In addition, mares had a greater (P < 0.0001) glucose response to dexamethasone than geldings. Cortisol concentrations were decreased (P = 0.029) by dexamethasone equally in all groups. In conclusion, differences in insulin, T3, and GH associated with high vs. low leptin concentrations indicate a likely interaction of these systems with leptin secretion in horses and serve as a starting point for future study of the cause-and-effect nature of the interactions.
Collapse
Affiliation(s)
- J A Cartmill
- Department of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge 70803, USA
| | | | | | | | | |
Collapse
|
40
|
Pruett HE, Thompson DL, Cartmill JA, Williams CC, Gentry LR. Thyrotropin releasing hormone interactions with growth hormone secretion in horses. J Anim Sci 2003; 81:2343-51. [PMID: 12968710 DOI: 10.2527/2003.8192343x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Light horse mares, stallions, and geldings were used to 1) extend our observations on the thyrotropin releasing hormone (TRH) inhibition of GH secretion in response to physiologic stimuli and 2) test the hypothesis that stimulation of endogenous TRH would decrease the normal rate of GH secretion. In Exp. 1 and 2, pretreatment of mares with TRH (10 microg/kg BW) decreased (P < 0.001) the GH response to exercise and aspartate infusion. Time analysis in Exp. 3 indicated that the TRH inhibition lasted at least 60 min but was absent by 120 min. Administration of a single injection of TRH to stallions in Exp. 4 increased (P < 0.001) prolactin concentrations as expected but had no effect (P > 0.10) on GH concentrations. Similarly, 11 hourly injections of TRH administered to geldings in Exp. 5 did not alter (P > 0.10) GH concentrations either during the injections or for the next 14 h. In Exp. 5, it was noted that the prolactin and thyroid-stimulating hormone responses to TRH were great (P < 0.001) for the first injection, but subsequent injections had little to no stimulatory effect. Thus, Exp. 6 was designed to determine whether the inhibitory effect of TRH also waned after multiple injections. Geldings pretreated with five hourly injections of TRH had an exercise-induced GH response identical to that of control geldings, indicating that the inhibitory effect was absent after five TRH injections. Retrospective analysis of pooled, selected data from Exp. 4, 5, and 6 indicated that endogenous GH concentrations were in fact lower (P < 0.01) from 45 to 75 min after TRH injection but not thereafter. In Exp. 7, 6-n-propyl-2-thiouracil was fed to stallions to reduce thyroid activity and hence thyroid hormone feedback, potentially increasing endogenous TRH secretion. Treated stallions had decreased (P < 0.01) concentrations of thyroxine and elevated (P < 0.01) concentrations of thyroid-stimulating hormone by d 52 of feeding, but plasma concentrations of GH and prolactin were unaffected (P > 0.10). In contrast, the GH response to aspartate and the prolactin response to sulpiride were greater (P < 0.05) in treated stallions than in controls. In summary, TRH inhibited exercise- and aspartate-induced GH secretion. The duration of the inhibition was at least 1 h but less than 2 h, and it waned with multiple injections. There is likely a TRH inhibition of endogenous GH episodes as well. Reduced thyroid feedback on the hypothalamic-pituitary axis did not alter basal GH and prolactin secretion.
Collapse
Affiliation(s)
- H E Pruett
- Department of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge 70803-4210, USA
| | | | | | | | | |
Collapse
|
41
|
Johnson PJ, Messer NT, Ganjam VK, Thompson DL, Refsal KR, Loch WE, Ellersieck MR. Effects of propylthiouracil and bromocryptine on serum concentrations of thyrotrophin and thyroid hormones in normal female horses. Equine Vet J 2003; 35:296-301. [PMID: 12755434 DOI: 10.2746/042516403776148309] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
REASONS FOR PERFORMING STUDY There exists a need for better diagnostic tests to characterise thyroid disease in horses. Currently available diagnostic tests fail to differentiate between thyroid gland disorders and thyroid abnormalities resulting from pituitary or hypothalamic problems. OBJECTIVES To evaluate the effects of treatment with propylthiouracil (PTU) and bromocryptine (BROM) on serum concentrations of triiodothyronine (T3), thyroxine (T4), reverse T3 (rT3) and equine thyroid-stimulating hormone (e-TSH, thyrotrophin) in mature horses. METHODS Healthy mature horses were treated using either PTU or BROM for 28 days. The effect of treatment on the thyroid axis was assessed by measuring T3, T4, rT3 and e-TSH before and at +14 and +28 days. The effect of PTU and BROM on the response of T3, T4, rT3 and e-TSH to thyrotrophin-release hormone (TRH) administration was also assessed before and at +14 and +28 days of treatment. RESULTS Treatment with PTU led to a significant reduction in serum concentrations of T3, T4 and rT3 on Day 28 and increase of e-TSH on Day 28 (P < 0.05). Treatment with BROM did not cause any measurable effect on serum concentrations of T3, T4, rT3 or e-TSH. The percentage increment by which serum concentration of T4, T3 and e-TSH increased following stimulation with TRH was decreased by treatment with PTU for 28 days (P < 0.05) but were not affected by treatment with BROM for 28 days. CONCLUSIONS These results suggest that 1) treatment with PTU may be used in horses as a model of primary hypothyroidism; 2) the use of BROM as a model of secondary hypothyroidism in horses is not supported; and 3) e-TSH assay deserves further investigation for the clinical diagnosis of thyroid axis dysfunction in horses. POTENTIAL RELEVANCE Propylthiouracil effectively causes primary hypothyroidism. There is substantial variability between horses with respect to their sensitivity to this substance when administered orally. Further studies pertaining to the characterisation of equine thyroid disorders are warranted and the use of both PTU for the experimental induction of primary hypothyroidism and e-TSH for the diagnostic characterisation of thyroid disorders in horses should be considered.
Collapse
Affiliation(s)
- P J Johnson
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | | | | | | | | | | | | |
Collapse
|
42
|
Johnson CA, Thompson DL, Cartmill JA. Effects of deslorelin acetate implants in horses: single implants in stallions and steroid-treated geldings and multiple implants in mares. J Anim Sci 2003; 81:1300-7. [PMID: 12772858 DOI: 10.2527/2003.8151300x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Three experiments were performed to test the following hypotheses: 1) stallions and/or progesterone-estradiol-treated geldings could serve as models for the effects of a single implant of the GnRH analog, deslorelin acetate, on LH and FSH secretion by mares; and 2) multiple implants of deslorelin acetate could be used as a means of inducing ovarian atrophy in mares for future study of the mechanisms involved in the atrophy observed in some mares after a single implant. In Exp. 1, nine light horse stallions received either a single deslorelin implant (n = 5) or a sham injection (n = 4) on d 0. In Exp. 2, 12 geldings received daily injections of progesterone on d -20 through -4, followed by twice-daily injections of estradiol on d -2 to 0. On the morning of d 0, geldings received either a single deslorelin implant (n = 6) or a sham injection (n = 6). Daily injections of progesterone were resumed on d 2 through 15. In Exp. 1, plasma LH and FSH were elevated (P < 0.05) in the treatment group relative to controls at 4, 8, and 12 h after implant insertion. In the treated stallions, FSH was decreased (P < 0.05) on d 3 to 13, and LH was decreased on d 6 to 13. In Exp. 2, plasma LH and FSH were elevated (P < 0.05) at 4,8, and 12 h after deslorelin implant insertion. Plasma LH was suppressed (P < 0.05) below controls on d 2 to 7, 9, and 11 to 15; plasma FSH was suppressed (P < 0.05) on d 4 to 15. In Exp. 3, 21 mares were used to determine whether multiple doses of deslorelin would cause ovarian atrophy. Mares received one of three treatments: 1) sham injections; 2) three implants on the first day; or 3) one implant per day for 3 d (n = 7 per group). Treatment with multiple implants increased (P < 0.05) the interovulatory interval by 14.8 d and suppressed (P < 0.01) LH and FSH concentrations for approximately 25 d; no mare exhibited ovarian atrophy. In conclusion, after an initial short-term increase in LH and FSH secretion, deslorelin implants caused long-term suppression of both gonadotropins in stallions as well as in geldings treated with progesterone and estradiol to mimic the estrous cycle. It is likely that either of these models may be useful for further study of this suppression in horses. Although multiple implants in mares suppressed gonadotropin secretion longer than a single implant, the lack of ovarian atrophy indicates that the atrophy observed after a single implant in previous experiments was likely due to the susceptibility of individual mares.
Collapse
Affiliation(s)
- C A Johnson
- Department of Animal Science, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge 70803-4210, USA
| | | | | |
Collapse
|
43
|
Thompson DL, Gerlach-Bank LM, Barald KF, Koenig RJ. Retinoic acid repression of bone morphogenetic protein 4 in inner ear development. Mol Cell Biol 2003; 23:2277-86. [PMID: 12640113 PMCID: PMC150746 DOI: 10.1128/mcb.23.7.2277-2286.2003] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2002] [Revised: 01/02/2003] [Accepted: 01/08/2003] [Indexed: 11/20/2022] Open
Abstract
Bone morphogenetic protein 4 (BMP4) and retinoic acid are important for normal development of the inner ear, but whether they are linked mechanistically is not known. BMP4 antagonists disrupt semicircular canal formation, as does exposure to retinoic acid. We demonstrate that retinoic acid directly down-regulates BMP4 transcription in a mouse inner ear-derived cell line, and we identify a novel promoter in the second intron of the BMP4 gene that is a target of this regulation both in the cell line and in the mouse embryonic inner ear in vivo. The importance of this down-regulation is demonstrated in chicken embryos by showing that the retinoic acid effect on semicircular canal development can be overcome by exogenous BMP4.
Collapse
MESH Headings
- Animals
- Benzoates/pharmacology
- Bone Morphogenetic Protein 4
- Bone Morphogenetic Proteins/antagonists & inhibitors
- Bone Morphogenetic Proteins/pharmacology
- Bone Morphogenetic Proteins/physiology
- Cell Line
- Chick Embryo
- Ear, Inner/cytology
- Ear, Inner/drug effects
- Ear, Inner/embryology
- Ear, Inner/metabolism
- Gene Expression Regulation, Developmental/drug effects
- Gene Expression Regulation, Developmental/physiology
- Introns
- Mice
- Promoter Regions, Genetic/physiology
- RNA/metabolism
- Receptors, Retinoic Acid/genetics
- Receptors, Retinoic Acid/metabolism
- Retinoic Acid Receptor alpha
- Retinoids/pharmacology
- Transcription, Genetic/physiology
- Tretinoin/pharmacology
- Tretinoin/physiology
Collapse
Affiliation(s)
- Deborah L Thompson
- Department of Internal Medicine, Endocrinology Division, University of Michigan, Ann Arbor, Michigan 48109-0678, USA
| | | | | | | |
Collapse
|
44
|
Cartmill JA, Thompson DL, Gentry LR, Pruett HE, Johnson CA. Effects of dexamethasone, glucose infusion, adrenocorticotropin, and propylthiouracil on plasma leptin concentrations in horses. Domest Anim Endocrinol 2003; 24:1-14. [PMID: 12450621 DOI: 10.1016/s0739-7240(02)00183-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
In experiment 1, nine light horse geldings (three 3 x 3 Latin squares) received dexamethasone (DEX; 125 microg/kg BW, i.m.), glucose (0.2 g/kg BW, i.v.), or nothing (control) once per day for 4 days. DEX increased (P < 0.001) glucose, insulin, and leptin concentrations and resulted in a delayed increase (P < 0.001) in IGF-I concentrations. In experiment 2, mares were similarly treated with DEX (n = 6) or vehicle (n = 6). DEX again increased (P < 0.01) glucose, insulin, and leptin concentrations; the delayed elevation in IGF-I concentrations occurred on day 10, 12, and 19, relative to the first day of treatment. In experiment 3, six light horse geldings received either 200 IU of adrenocorticotropin (ACTH) i.m. or vehicle twice daily for 4 days. ACTH increased (P < 0.001) cortisol concentrations. Further, ACTH resulted in increases (P < 0.01) glucose, insulin, and leptin concentrations. In experiment 4, plasma samples from four light horse stallions that were fed 6-n-propyl-2-thiouracil (PTU) at 6 mg/kg BW for 60 days to induce hypothyroidism were compared to samples from control stallions. On day 52, stallions receiving PTU had lower concentrations of thyroxine (P < 0.05) and triiodothyronine (P < 0.01) and higher (P < 0.01) concentrations of TSH. Leptin concentrations were higher (P < 0.01) in PTU-fed stallions from day 10 through 52. In conclusion, circulating concentrations of leptin in horses was increased by administering DEX. Treatment with ACTH increased cortisol and resulted in lesser increases in leptin, glucose, and insulin. In addition, PTU feeding results in lesser increases in leptin concentrations.
Collapse
Affiliation(s)
- J A Cartmill
- Department of Animal Science, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge, LA 70803, USA
| | | | | | | | | |
Collapse
|
45
|
Gentry LR, Thompson DL, Gentry GT, Davis KA, Godke RA. High versus low body condition in mares: interactions with responses to somatotropin, GnRH analog, and dexamethasone. J Anim Sci 2002; 80:3277-85. [PMID: 12542169 DOI: 10.2527/2002.80123277x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Mares that had previously been fed to attain body condition scores (BCS) of 7.5 to 8.5 (high) or 3.0 to 3.5 (low) were used to determine the interaction of BCS with the responses to 1) administration of equine somatotropin (eST) daily for 14 d beginning January 20 followed by administration of GnRH analog (GnRHa) daily for 21 d and 2) 4-d treatment with dexamethasone later in the spring when mares in low BCS had begun to ovulate. The majority of mares with high BCS continued to cycle throughout the winter, as evidenced by larger ovaries (P < 0.002), more corpora lutea (P < 0.05), greater progesterone concentrations during eST treatment (P < 0.04), and more (P < 0.05) large- and medium-sized follicles. Treatment with eST alone or in combination with GnRHa had no effect (P > 0.05) on ovarian activity or ovulation. Plasma leptin concentrations were greater (P < 0.002) in mares with high BCS; however, there was no effect (P > 0.10) of eST treatment. Plasma IGF-I concentrations were greater (P < 0.0001) in mares treated with eST compared with mares given vehicle, and mares with high BCS had greater IGF-I (P < 0.02) and LH concentrations (P < 0.02) than mares with low BCS. Plasma leptin concentrations in mares with high BCS were increased (P < 0.001) within 12 h of dexamethasone treatment; the leptin response (P < 0.001) in mares with low BCS was greatly reduced (P < 0.001) and transient. Glucose and insulin concentrations also increased (P < 0.0001) after dexamethasone treatment in both groups, and the magnitude of the response was greater (P < 0.0001) in mares with high BCS than in mares with low BCS. In summary,low BCS in mares was associated with a consistent seasonal anovulatory state that was affected little by eST and GnRHa administration. In contrast, all but one mare with high BCS continued to experience estrous cycles and(or) have abundant follicular activity on their ovaries. The IGF-I response to eST treatment was also reduced in mares with low BCS, as was the basal leptin concentration and leptin response to dexamethasone. Although low BCS and leptin concentrations were associated with inactive ovaries during winter and early spring, mares with low BCS eventually ovulated in April and May while leptin concentrations remained low.
Collapse
Affiliation(s)
- L R Gentry
- Department of Animal Science, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge 70803-4210, USA
| | | | | | | | | |
Collapse
|
46
|
Abstract
The present experiment characterized the pituitary responsiveness to exogenous GnRH in the first 10 d after ovulation following commercially available deslorelin acetate implantation at the normal dosage for hastening ovulation in mares. Twelve mature, cyclic mares were assessed daily for estrus and three times weekly for ovarian activity starting May 1. Mares achieving a follicle at least 25 mm in diameter or showing signs of estrus were checked daily thereafter for ovarian characteristics. When a follicle >30 mm was detected, mares were administered either a single deslorelin acetate implant or a sham injection and then assessed daily for ovulation. On d 1, 4, 7, and 10 following ovulation, each mare was challenged i.v. with 50 microg GnRH, and blood samples were collected to characterize the LH and FSH responses. The size of the largest follicle on the day of treatment did not differ (P = 0.89) between groups. The number of days from treatment to ovulation was shorter (P < 0.001) by 2.0 d for the treated mares indicating a hastening of ovulation. The size of the largest follicle present on the days of GnRH challenge was larger in the treated mares on d 1 (P = 0.007) but smaller on d 10 (P = 0.02). In addition, the interovulatory interval was longer (P = 0.036) in the treated mares relative to controls by 4.4 d. Concentrations of FSH in plasma of the treated mares were lower (P < 0.05) than control concentrations from d 3 to 12; LH concentrations in the treated mares were lower (P < 0.05) relative to controls on d 0 to 5, d 7, and again on d 20 to 23. Progesterone values were the same (P = 0.99) for both groups from 2 d before ovulation though d 23. There was an interaction of treatment, day, and time of sampling (P < 0.001) for LH and FSH concentrations after injection of GnRH. Both the LH and FSH responses were suppressed (P < 0.009) in the treated mares relative to controls on d 1, 4, and 7; by d 10, the responses of the two groups were equivalent. In conclusion, deslorelin administration in this manner increased the interovulatory interval, consistently suppressed plasma LH and FSH concentrations, and resulted in a complete lack of responsiveness of LH and FSH to GnRH stimulation at the dose used during the first 7 d after the induced ovulation. Together, these results are consistent with a temporary down-regulation of the pituitary gland in response to deslorelin administered in this manner.
Collapse
Affiliation(s)
- C A Johnson
- Department of Animal Science, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge 70803-4210, USA
| | | | | |
Collapse
|
47
|
Gentry LR, Thompson DL, Gentry GT, Davis KA, Godke RA, Cartmill JA. The relationship between body condition, leptin, and reproductive and hormonal characteristics of mares during the seasonal anovulatory period. J Anim Sci 2002; 80:2695-703. [PMID: 12413093 DOI: 10.2527/2002.80102695x] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
An experiment was conducted to determine the effects of high vs low body condition scores (BCS) produced by restricted feeding on reproductive characteristics, hormonal secretion, and leptin concentrations in mares during the autumnal transition and winter anovulatory period. Mares with BCS of 6.5 to 8.0 were maintained on pasture and/or grass hay, and starting in September, were full fed or restricted to produce BCS of 7.5 to 8.5 (high) or 3.0 to 3.5 (low) by December. All but one mare with high BCS continued to ovulate or have follicular activity during the winter, whereas mares with low BCS went reproductively quiescent. Plasma leptin concentrations varied widely before the onset of restriction, even though all mares were in good body condition. During the experiment, leptin concentrations gradually decreased (P < 0.0001) over time in both groups, but were higher (P < 0.009) in mares with high vs low BCS after 6 wk of restriction, regardless of initial concentration. No differences (P > 0.1) between groups were detected for plasma concentrations of LH, FSH, TSH, GH, glucose, or insulin in samples collected weekly; in contrast, plasma prolactin concentrations were higher (P < 0.02) in mares with high BCS, but also decreased over time (P < 0.008). Plasma IGF-I concentrations tended (P = 0.1) to be greater in mares with high vs low BCS. The prolactin response to sulpiride injection on January 7 did not differ (P > 0.1) between groups. During 12 h of frequent blood sampling on January 12, LH concentrations were higher (P < 0.0001), whereas GH concentrations (P < 0.0001) and response to secretagogue (EP51389; P < 0.03) were lower in mares with high BCS. On January 19, the LH response to GnRH was higher (P < 0.02) in mares with high BCS; the prolactin response to TRH also was higher (P < 0.01) in mares with high BCS. In conclusion, nutrient restriction resulting in low BCS in mares resulted in a profound seasonal anovulatory period that was accompanied by lower leptin, IGF-I, and prolactin concentrations. All but one mare with high BCS continued to cycle throughout the winter or had significant follicular activity on the ovaries. Although leptin concentrations on average are very low in mares with low BCS and higher in well-fed mares, there is a wide variation in concentrations among well-fed mares, indicating that some other factor(s) may determine leptin concentrations under conditions of high BCS.
Collapse
Affiliation(s)
- L R Gentry
- Department of Animal Science, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge 70803-4210, USA
| | | | | | | | | | | |
Collapse
|
48
|
Abstract
Two experiments compared the efficacies of different treatment frequencies for recombinant equine somatotropin (eST). In Experiment 1, five geldings received daily injections of eST at 20 microg/kg of body weight, and five received every-other-day injections at 40 microg/kg of body weight, for a total of 30 days. Plasma glucose (P=0.0001), insulin (P=0.0135), and non-esterified fatty acid (NEFA, P=0.0001) concentrations increased, and plasma urea nitrogen (PUN) concentrations decreased (P=0.0001), in both groups, and only minor differences (P<0.05) occurred between the two groups. Insulin-like growth factor-I (IGF-I) concentrations increased (P=0.0001) in both groups over time, and were higher (P<0.05) after day 2 in geldings treated daily. Endogenous somatotropin (ST) response to secretagogue was inhibited (P<0.05) in geldings receiving daily injections relative to those receiving every-other-day injections. In Experiment 2, 16 geldings were allotted to four groups of four. A control group received daily saline injections, and the other three groups received eST at 20 microg/kg of body weight daily as a single injection, two injections (every 12h), or four injections (every 6h), for a total of 14 days. Plasma IGF-I and insulin concentrations increased (P<0.05) in all groups receiving eST, with the responses being proportional to injection frequency. In contrast, PUN concentrations decreased (P<0.05) in all groups equally. In conclusion, the efficacy of daily versus every-other-day injections of eST depends upon the response to be measured, and for IGF-I concentrations, the every-other-day regimen was not acceptable. Injection frequencies greater than once daily were more efficacious for IGF-I and insulin concentrations, but not for PUN concentrations. Thus, the optimum injection regimen for any new application for eST cannot simply be inferred from other biological responses, and will need to be determined empirically.
Collapse
Affiliation(s)
- C E Thatcher
- Department of Animal Science, Louisiana Agricultural Experiment Station, LSU Agricultural Center, Baton Rouge, LA, USA
| | | |
Collapse
|
49
|
Ellsworth JL, Berry J, Bukowski T, Claus J, Feldhaus A, Holderman S, Holdren MS, Lum KD, Moore EE, Raymond F, Ren H, Shea P, Sprecher C, Storey H, Thompson DL, Waggie K, Yao L, Fernandes RJ, Eyre DR, Hughes SD. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage 2002; 10:308-20. [PMID: 11950254 DOI: 10.1053/joca.2002.0514] [Citation(s) in RCA: 141] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE The aim of this study was to examine the effects of recombinant human Fgf18 on chondrocyte proliferation and matrix production in vivo and in vitro. In addition, the expressions of Fgf18 and Fgf receptors (Fgfr) in adult human articular cartilage were examined. METHODS Adenovirus-mediated transfer of Fgf18 into murine pinnae and addition of FGF18 to primary cultures of adult articular chondrocytes were used to assess the effects of FGF18 on chondrocytes. In situ hybridization was used to examine the expression of Fgf18 and Fgfr s in adult human articular cartilage. RESULTS Expression of Fgf18 by adenovirus-mediated gene transfer in murine pinnae resulted in a significant increase in chondrocyte number. Chondrocytes were identified by staining with toluidine blue and a monoclonal antibody directed against type II collagen. Fgf18, Fgfr 2-(IIIc), Fgfr 3-(IIIc), and Fgfr 4 mRNAs were detected within these cells by in situ hybridization. The nuclei of the chondrocytes stained with antibodies to PCNA and FGF receptor (FGFR) 2. Addition of FGF18 to the culture media of primary articular chondrocytes increased the proliferation of these cells and increased their production of extracellular matrix. To assess the receptor selectivity of FGF18, BaF3 cells stably expressing the genes for the major splice variants of Fgfr1-3 were used. Proliferation of cells expressing Fgfr 3-(IIIc) or Fgfr 2-(IIIc) was increased by incubation with FGF18. Using FGFR-Fc fusion proteins and BaF3 cells expressing Fgfr 3-(IIIc), only FGFR 3-(IIIc)-Fc, FGFR 2-(IIIc)-Fc or FGFR 4-Fc reduced FGF18-mediated cell proliferation. Expression of Fgf18, Fgfr 3-(IIIc) and Fgfr 2-(IIIc) mRNAs was localized to chondrocytes of human articular cartilage by in situ hybridization. CONCLUSION These data demonstrate that Fgf18 can act as a trophic factor for elastic chondrocytes and their progenitors in vivo and articular chondrocytes cultured in vitro. Expression of Fgf18 and the genes for two of its receptors in chondrocytes suggests that Fgf18 may play an autocrine role in the biology of normal articular cartilage.
Collapse
Affiliation(s)
- J L Ellsworth
- ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, Washington 98102, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kennedy SR, Thompson DL, Pruett HE, Burns PJ, Deghenghi R. Growth hormone response to a novel growth hormone-releasing tripeptide in horses: interaction with gonadotropin-releasing hormone, thyrotropin-releasing hormone, and sulpiride. J Anim Sci 2002; 80:744-50. [PMID: 11890411 DOI: 10.2527/2002.803744x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
A series of experiments was performed to determine the factor(s) responsible for an apparent inhibition of GH secretion in mares administered the GH secretagogue EP51389 in combination with GnRH, thyrotropin-releasing hormone (TRH), and sulpiride. Experiment 1 tested the repeatability of the original observation: 10 mares received EP51389 at 10 microg/kg BW; five received TRH (10 microg/kg BW), GnRH (1 microg/kg BW), and sulpiride (100 microg/kg BW) immediately before EP51389, and five received saline. The mixture of TRH, GnRH, and sulpiride reduced (P = 0.0034) the GH response to EP51389, confirming the inhibitory effects. Experiment 2 tested the hypothesis that sulpiride, a dopamine antagonist, was the inhibitory agent. Twelve mares received EP51389 as in Exp. 1; six received sulpiride before EP51389 and six received saline. The GH responses in the two groups were similar (P > 0.1), indicating that sulpiride was not the inhibitory factor. Experiment 3 tested the effects of TRH and(or) GnRH in a 2 x 2 factorial arrangement of treatments. Three mares each received saline, TRH, GnRH, or the combination before EP51389 injection. There was a reduction (P < 0.0001) in GH response in mares receiving TRH, whereas GnRH had no effect (P > 0.1). Given those results, Exp. 4 was conducted to confirm that TRH was inhibitory in vivo as opposed to some unknown chemical interaction of the two compounds in the injection solution. Twenty mares received TRH or saline and(or) EP51389 or saline in a 2 x 2 factorial arrangement of treatments. Injections were given separately so that the two secretagogues never came in contact before injection. Again, TRH reduced (P < 0.0001) the GH response to EP51389. In addition, TRH and EP51389 each resulted in a temporary increase in cortisol concentrations. Experiment 5 tested whether TRH would alter the GH response to GHRH itself. Twelve mares received porcine GHRH at 0.4 microg/kg BW; six received TRH prior to GHRH and six received saline. After adjustment for pretreatment differences between groups, the GHRH-induced GH response was completely inhibited (P = 0.068) by TRH. Exp. 6 was a repeat of Exp. 5, except geldings were used (five per group). Again, pretreatment with TRH inhibited (P < 0.0001) the GH response to GHRH. In conclusion, TRH inhibits the GH response not only to EP51389 but also to GHRH in horses, and in addition to its known secretagogue action on prolactin and TSH it may also stimulate ACTH at the dosage used in these experiments.
Collapse
Affiliation(s)
- S R Kennedy
- Department of Animal Science, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Baton Rouge 70803-4210, USA
| | | | | | | | | |
Collapse
|